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Chapter 1 
Introduction 
 
1.1 Overview of CXCR2 Chemokine Receptor 
1.1.1 Chemokines and Chemokine Receptors 
Chemokines are a family of small cytokines that are responsible for directed cellular 
chemotaxis. Chemokines can be divided into two categories: inflammatory chemokines 
that recruit leukocytes in response to physiological stimulus and homeostatic 
chemokines that are constitutively expressed, and responsible for the continuous basal 
level of cell migration and the architecture of secondary lymphoid organs1. Inflammatory 
chemokines and their receptors have pivotal roles in both innate and adaptive immunity 
in response to infection, tissue damage, and other physiological abnormalities. 
Homeostatic chemokines involve in the migration of B and T cells through specialized 
areas of secondary lymphoid organs, and migration of lymphocytes involved in immune 
surveillance2. In spite of the critical roles of chemokines and their receptors in the 
immune system, they have been documented to be actively involved in enormous 
pathologies1,3,4, including inflammatory diseases (inflammatory bowel disease, 
atherosclerosis), pulmonary diseases (chronic obstructive pulmonary disease (COPD), 
asthma), autoimmune diseases (psoriasis, rheumatoid arthritis, and multiple sclerosis), 
and cancers.  
 
To date, approximately 50 chemokines and 20 corresponding chemokine receptors 
have been identified. Based on the conserved pattern of cysteine residues at N-
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terminus, chemokines have been divided into four different subfamilies: C, CC, CXC, 
and CX3C, where C represents cysteine residue, and X represents any non-cysteine 
residue. In human, there are 7 CXC subfamily chemokine receptors (CXCR1 ~ CXCR7), 
and 15 cognate CXC chemokines (or CXCR ligands). CXCR2, a prototypical member of 
the CXC chemokine receptors, was first discovered as a neutrophil receptor5. Years of 
intensive research has also delineated its roles in a variety of diseases including cancer 
and inflammatory diseases. Furthermore, several pharmaceutical companies have 
identified a number of potent CXCR2 antagonists that have been evaluated in the 
clinical trials. However, many clinical trials of CXCR2 antagonists/inhibitors have not 
been successful due to the suboptimal clinical endpoints. Recent studies targeting 
compartmentalized interactions of CXCR2 complexes inside the cells open the door for 
development of a new class of CXCR2 inhibitors, which target the specific interactions 
between CXCR2 and its binding partners. This chapter focuses on the most recent 
progress about the interactions between CXCR2 and its interacting partners, and the 
fine-tuned regulation of CXCR2 compartmentalized signalings in inflammation, cancer, 
and angiogenesis. 
 
1.1.2 CXCR2 Structure 
CXCR2 was first designated as IL-8 receptor type B (IL-8RB) by Murphy and his 
colleagues5, sharing 77% identity with another closely-related receptor IL-8RA (also 
known as CXCR1) at the amino acid sequence level. CXCR2 is a G protein-coupled 
receptor which is composed of seven transmembrane domains, an extracellular N-
terminal domain, three extracellular loops, three intracellular loops, and a cytoplasmic 
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C-terminus (Fig. 1 - 1). The extracellular N-terminal domain is involved in ligand binding, 
and the DRY (Asp-Arg-Tyr) motif in the second intracellular loop is the G protein 
docking site, and is responsible for intracellular downstream signaling upon ligand 
binding6. Also, the Asp 199 in the second extracellular loop7 and an LLKIL motif in the 
C-terminus8 are both required for receptor internalization. 
 
1.1.3 CXCR2 Ligands and Signaling 
CXCR2 is the cognate receptor for the CXC chemokines CXCL1 ~ 3 and CXCL5 ~ 8 
(also referred to as CXCR2 ligands)9. The characteristic ELR (Glu-Leu-Arg) motif 
located in the N terminus of the CXCR2 ligands are responsible for the ligand-receptor 
binding10, and is strongly associated with the leukocyte attraction11. Although further 
structural studies regarding the ligand-receptor interaction of CXCR2 are still in need, 
the binding mechanism has been proposed based on modeling and structural studies of 
CXCR4 and CCR2 binding modes12,13. Conceptually, the binding involves the binding 
between N-terminal residues from both the receptor and its ligands (preceding the 1st 
cysteine), followed by the interaction of the ELR motif of the ligands with the 2nd and 3rd 
extracellular loops of the receptor. N-terminus of the receptor is responsible for the 
binding selectivity and affinity14, whereas the ELR motif from the ligands enables the 
stabilization of the binding interaction and leads to the activation of the downstream 
signaling cascade15. Upon ligand-receptor binding, the heterotrimeric G protein is 
activated, whereby the α-subunit and βγ-complex dissociate, leading to the activation or 
inhibition of a wide variety of downstream targets (phospholipase C, adenylyl cyclase, 
cAMP-dependent protein kinase, GTPases, PI3K, etc.). CXCR2 has been implicated in 
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activation of several signaling transduction pathways, including phospholipase C (PLC) 
pathway, PI3K pathway, and Rho, Rac and mitogen activated protein kinase (MAPK) 
pathways16. 
 
1.1.4 Roles of CXCR2 Biological Axis 
Signaling pathways evoked by the activation of CXCR2 have been borne out to play 
important roles in a variety of cellular responses, including cell migration, chemotaxis, 
cell adhesion, cellular morphological change, cytoskeletal rearrangement, etc17. The 
expression of CXCR2 on leukocytes, especially neutrophils, has been well-established 
for its roles in leukocyte homeostasis as well as the recruitment of leukocytes from bone 
marrow in respond to inflammation and injury18-20. CXCR2 had also been reported in 
preservation of oligodendrocyte function and myelinization of neural tissues21. 
Furthermore, CXCR2 and its ligands have also been demonstrated to play essential 
roles in cutaneous wound healing22. 
 
1.2 CXCR2 in Diseases and Its Clinical Significance 
1.2.1 CXCR2 in inflammatory diseases 
Although the recruitment of neutrophils, which is regulated primarily by CXCR2, is 
important in response to acute inflammation and injury19,20, persistent or over-exuberant 
expression of CXCR2 and its ligands could subvert the protective effects of neutrophils 
into a manner that cause diseases, since excessive neutrophil influx and accumulation 
at the inflammation sites is well-believed to play crucial roles in pathogenic progression 
of clinical and experimental inflammatory diseases. Therefore, CXCR2 has been widely 
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demonstrated to play important role in various inflammatory diseases, including chronic 
obstructive pulmonary disease (COPD), acute lung injury (ALI), cystic fibrosis (CF), 
inflammatory bowel diseases (IBD), and ischemia-reperfusion injury. Increased 
expression of CXCR2 and its cognate CXC chemokines have been reported in recent 
clinical studies in various inflammatory disease systems, suggesting the clinical 
significance of CXC chemokine/CXCR2 biological axis.  
 
It has been documented that CXCR223,24 and its cognate ligands (CXCL125, CXCL523, 
CXCL723,24, CXCL826, and PGP27) are significantly up-regulated in the patients with 
severe COPD compared with healthy smokers and patients with mild/moderate COPD. 
It has been reported that the patients with acute respiratory distress syndrome (ARDS) 
has a dramatically higher concentration CXCL128, CXCL528 and CXCL828-30 in 
bronchoalveolar lavage fluid (BALF), and the level of the CXCL8: anti-CXCL8 antibody 
complexes profoundly correlated with the clinical disease activity31 and mortality29. CF 
patients also showed significantly elevated levels of CXCL8 in sputum, BALF, and sera, 
and the high level of CXCL8 significantly correlated with clinical status32. Expression 
levels of CXCR233,34 and its cognate ligands, CXCL133,34, CXCL233, CXCL333,34, 
CXCL535, and CXCL833,34,36-38, in the patients with IBD were substantially higher than 
the control individuals. Clinically, neutrophil-mediated reperfusion injury significantly 
increased mortality and morbidity when patients underwent ischemia-reperfusion 
injury (I/R-I) such as organ transplantation39,40 and cardiopulmonary bypass41. CXCR2 
cognate ligands, CXCL342, CXCL742 and CXCL842-44 were enormously increased in the 
BALF from patients underwent lung transplantation compared to the control subjects, 
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and that high level of CXCL8 in the donor BALF profoundly correlated with the 
development of severe early graft dysfunction and with early recipient mortality44. 
Significantly increased CXCL8 was also detected in patients underwent 
cardiopulmonary bypass45. 
 
Laboratory investigations also showed that CXCR2 deficiency or CXCR2 blockage 
prevented the Polymorphonuclear neutrophil (PMN) recruitment/accumulation in various 
experimental disease models. In COPD model, Weathington et al. reported that a 
CXCR2 specific peptide (PGP) failed to induce neutrophil accumulation in CXCR2-/- 
mice27. Miller et al. also reported that CXCR2 deficiency substantially decreased mucus 
secretion in the BALF, which is associated with chronic bronchitis. In ALI, animal 
studies have reported that PMN recruitment in the lung was significantly decreased in 
CXCR2-/- mice46-49. Kordonowy et al. also reported that ALI was attenuated in the obese 
mice, in which neutrophil CXCR2 expression was dramatically decreased50. 
Furthermore, blockade of CXCR2 by neutralizing antibody also markedly reduced 
neutrophil accumulation in ALI models51,52. In IBD model, Buanne et al. reported that 
PMN infiltration into mucosa was prominently reduced in CXCR2-/- mice with limited 
degree of mucosal damage and reduced clinical symptoms53. Elevated CXCR2 
expression has been reported during post-lung transplantation I/R-I in rats42, and 
CXCR2 deficiency has demonstrated to reduce the impairment caused by I/R injury in 
different models54,55. Also, blockade of CXCR2 markedly prevented graft malfunction 
and inhibited neutrophil recruitment and accumulation in transplantation models42,56. 
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1.2.2 CXCR2 in Cancers 
Overexpression of CXCR2 has been detected in patients with various cancers including 
breast cancer57, laryngeal squamous cell carcinoma58, colon cancer59, prostate 
cancer60,61, pancreatic cancer62,63, lung adenocarcinoma64, ovarian cancer (associated 
with patient survival)65, nasopharyngeal carcinoma66 and brain tumor67. Besides, 
CXCR2 cognate ligands (CXCL1, CXCL5, and/or CXCL8) also overexpressed in 
patients with prostate cancer61, colon cancer59,68-70, breast cancer71,72, and pancreatic 
cancer73-75. Furthermore, overexpression of CXCR2 and/or its ligands prominently 
correlated with tumor stage, disease severity and patient survival in most cases. 
 
Recent studies using CXCR2-/- mice have reported that CXCR2 deficiency profoundly 
prevented primary tumor growth and spontaneous metastases in lung cancer76, 
inhibited human melanoma tumor growth and experimental lung metastasis77, and 
suppressed human prostate tumor growth in vivo78. Blockade of CXCR2, by either 
neutralizing antibodies or short hairpin RNA (shRNAs), also significantly suppressed the 
proliferation, invasion and tumor growth in vitro and in vivo in many cancer models67,79-82. 
 
Recent advances also suggest that CXCR2 not only contributed to the cancer cell 
biology, but also played important roles in the interplay between tumor cell and tumor 
microenvironment. For example, Jamieson et al. reported that inflammation-driven and 
spontaneous tumorigenesis in skin and intestine has been distinctively subsided in 
CXCR2-/- mice, in which tumor-associated leukocyte recruitment has also been 
attenuated83. 
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1.3 CXCR2 Antagonists and Therapeutic Implications 
Given the essential role of CXCR2 biological axis in inflammatory diseases and cancers, 
pharmacological studies targeting CXCR2 has dramatically increased over the last 
decade. Several pharmaceutical companies have developed potent and selective 
CXCR2 antagonists, and laboratory investigations have achieved significant progress 
on CXCR2 antagonists in various disease models. Chapman et al. reported that SCH-
527123, one of the CXCR2 allosteric inhibitors, significantly inhibited the neutrophil 
recruitment, mucus production, and goblet cell hyperplasia in a murine COPD model84. 
SCH-563705, another CXCR2 antagonist with similar structure with SCH-527123, has 
been demonstrated to reduce the arthritis disease severity in vivo85, and block the 
mammosphere formation ex vivo71. Singh et al. demonstrated the inhibitory effect of 
SCH-479833, with similar structure as SCH-527123, on tumor growth and angiogenesis 
in melanoma86 and colon cancer87 animal models. SB225002, a well-established 
competitive CXCR2 inhibitor, has also been reported to exert the inhibitory effect in 
inflammatory disease and cancer models. Braber et al. reported that SB225002 
significantly inhibited CXCL1-induced increase of myeloperoxidase (MPO) levels in 
pulmonary tissue88. SB-225002 has also been demonstrated to significantly reduce 
MPO activity, BALF neutrophil accumulation, and edma formation in the injured lung89. 
Herbold et al. demonstrated the inhibitory effect of SB225002 in alveolar neutrophil and 
exudate macrophage recruitment in mice in a lung injury model49. In breast cancer 
models, SB-225002 has also been reported to inhibit mammary epithelial cell 
migration90 and breast cancer cell invasion91. Two groups also reported SB656933, 
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another allosteric CXCR2 inhibitor, and its predecessor SB332235, could block the 
neutrophil activation, recruitment, and accumulation in COPD models88,92,93. SB265610, 
another allosteric CXCR2 inhibitor, has also been reported to suppress mammary tumor 
cell migration, myeloid cell recruitment and lung metastasis in breast cancer 
models80,94,95. Another CXCR2 inhibitor, SB-468477 developed by Glaxo-Smith-Kline, 
has been shown to inhibit monocyte migration in response to selective CXCR2 ligands, 
CXCL1, CXCL5 and CXCL796. Repertaxin, a CXCR2 inhibitor also known as Reparixin, 
was reported to block the neutrophil accumulation in a lung injury model, and abate the 
pancreatic cancer tumor growth in vivo97. DF2162, another allosteric CXCR2 inhibitor 
developed by Dompé S.P.A., has been reported to inhibit the arthritis in vivo with 
diminished neutrophil infiltration, oedema formation, and hypernociception98-100. Besides 
the effect on arthritis, DF2162 was also demonstrated to reduce the airway neutrophil 
transmigration, and improve lung pathology in lung fibrosis model101. G31P, as known 
as CXCL8(3–72)K11R, is an orthosteric inhibitor of CXCR2, which has been reported to 
fully abolish Benzo(a)pyrene triggered neutrophil recruitment in BALFs102. Liu et al. 
reported that G31P significantly suppressed prostate cancer cell proliferation both in 
vitro and in vivo103. AZ10397767, developed by AstraZeneca as a thiazolopyrimidine-
based CXCR2 antagonist, has been shown to suppress lung cancer growth with 
decreased neutrophil infiltration104, and sensitize prostate cancer cells to 
chemotherapy105. Furthermore, some of the CXCR2 antagonists have been progressed 
into clinical trials106,107. Some of the well-tested CXCR2 antagonists have been 
summarized in Table 1-1.  
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SCH-527123, developed by Schering-Plough, has been evaluated in several neutrophil 
dominant diseases including psoriasis (NCT00684593, phase II), asthma 
(NCT00688467, Phase II; NCT00632502, Phase II) and COPD (NCT01068145, Phase I; 
NCT00441701, Phase II). Holz et al. has reported that SCH-527123 caused significant 
attenuation of ozone-induced neutrophilia in healthy subjects108. Reparixin, developed 
by Dompé S.P.A., has also been tested in phase II clinical trials of I/R-I after lung and 
kidney transplantation, and in phase III clinical in pancreatic islet transplantation. SB-
656933, the derivative of SB-332235109 developed by GlaxoSmithKline, has also been 
assessed in several phase I/II COPD clinical trials. Moss et al. reported that SB656933 
was well-tolerated in adult CF patients, and significantly suppressed sputum neutrophil 
and elatase110. AZD-5069, developed by AstraZeneca, has also been evaluated in 
phase II clinical trials in COPD and bronchiectasis patients111. 
 
In spite of the availability of several databases of clinical trials, scant results of 
completed clinical trials have been publicly released. Termination or discontinuation of 
the trials might result from the difficulty in patient recruitment, financial issues, or failure 
to reach clinical end points107. Furthermore, small molecule drugs/antagonists targeting 
at chemokine receptors still face several challenges that have been well-discussed in 
the excellent review paper by Proudfoot et al, including the interspecies difference in 
antagonist potency, redundancy in receptor-ligand pairing and subsequent biological 
functions, suboptimal pharmacokinetic and toxicity profiles, and the inadequate ultimate 
curative effects107. 
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1.4 CXCR2 Macromolecular Complex – Identification and Therapeutic Potential 
Besides the challenges mentioned above, emphasis is also placed on identifying novel 
CXCR2 inhibitors, which can be more tissue-specific and/or disease-specific112, 
because CXCR2 functions in normal physiology (including early tumor surveillance and 
immune system physiology) have to be protected in any antagonist that will be 
advanced to clinical trials. Recent studies aiming at protein-protein interactions involving 
CXCR2 have explored some novel avenues for innovative drug discovery. It has been 
documented that chemokine receptors couple not only to G proteins but also to 
additional non-G proteins, especially the scaffolding proteins, which could provide 
binding sites for downstream effector proteins113, and direct CXCR2 to operate in 
specific signaling networks. With no doubt it would be beneficial if we could identify 
novel CXCR2-interacting proteins or tissue/disease specific interacting partners of 
CXCR2, which could enhance the CXCR2 signaling in certain disease conditions. By 
disrupting these protein-protein interactions of CXCR2, we may develop more effective 
treatment options. 
 
Recent advances have already revealed the functional importance of the CXCR2-
interacting partners in CXCR2 trafficking, recycling, signal transduction, and it has also 
been suggested that different repertoires of adaptor/scaffolding proteins binding to 
CXCR2 and other chemokine receptors at varying spatiotemporal points are, at least 
partially, responsible for the versatile biological/cellular responses in different disease 
conditions114. Richmond group has identified several CXCR2-interacting proteins, which 
associates with CXCR2 and modulate CXCR2 trafficking, signaling, and CXCR2-
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mediated cellular functions. Hsc/Hsp70 interacting protein (Hip) interacts with a C-
terminal domain of CXCR2 (KILAIHGLI; i.e. a.a 327 ~ a.a 335), and affects CXCR2-
mediated chemotaxis115. Several Ras-related proteins (Rab), including Rab5, Rab11a, 
and Rab11-family interacting protein 2 (Rab11-FIP2), and Rho GTP-binding protein 
(RhoB) were also shown to bind CXCR2, and play important roles in CXCR2 trafficking, 
recycling and CXCR2-mediated chemotaxis116-118. β-arrestin 2, a member of arrestin 
family of adaptor proteins, has been demonstrated to bind phosphorylated carboxyl-
regions of CXCR1 and CXCR2, and modulate receptor internalization and activation of 
signal transduction pathways119,120. Besides β-arrestin 2, other scaffolding proteins, 
such as vasodilator-stimulated phosphoprotein (VASP)121, LIM and SH3 protein-1 
(LASP-1)122, and Ras GTPase-activating-like protein (IQGAP1)114, were also identified 
by proteomics approaches to associate with CXCR2, and regulate CXCR2-mediated 
signaling and chemotaxis. Furthermore, it has been unveiled that the C-terminal 
cytoplasmic domain of CXCR2, which contains several specific motifs (amino acid 
sequences) such as LLKIL motif8, PDZ motif (-STTL)123 and phosphorylation sites, is 
responsible for CXCR2 signaling, post-endocytic sorting, and/or CXCR2-mediated 
cellular chemotaxis. These studies not only led to identification of novel CXCR2-
interacting partners and the critical motifs in CXCR2 responsible for the binding, but 
also revealed the functional significance of the coordinated regulation of CXCR2 
signaling by these CXCR2-interacting partners, suggesting the therapeutic potential for 
targeting CXCR2-specific protein interactions. 
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Recently, we have also identified a PDZ domain-containing protein, Na+/H+ exchange 
regulatory cofactor (NHERF1), as a novel CXCR2-interacting protein. NHERF1 
associates with CXCR2 by PDZ interaction, and clusters the downstream effector, PLC-
β2, into a CXCR2 macromolecular complex (CXCR2•NHERF1•PLC-β2) in neutrophils124. 
The formation of this CXCR2 complex is PDZ motif-dependent (i.e. –STTL-COOH for 
CXCR2; -ESRL-COOH for PLC-β2). An exogenous CXCR2 C-terminal domain containing 
PDZ motif (last 45 amino acids or last 13 amino acids) was demonstrated to compete 
and disrupt the physical interaction between CXCR2 and NHERF1, and also were 
shown to impair the CXCR2-mediated intracellular calcium mobilization, chemotaxis, 
and transepithelial migration in neutrophils. We also identified another CXCR2 
macromolecular complex (CXCR2•NHERF1•PLC-β3) in human pancreatic ductal 
adenocarcinoma cells (PDACs), gene delivery or peptide delivery of exogenous CXCR2 
C-terminal domain (last 45 or 13 amino acids) impaired cancer cell invasion and cell 
proliferation in vitro and in vivo 125.  
 
Most recently, we also demonstrated the importance of CXCR2 PDZ-mediated protein 
interactions in the function of endothelial progenitor cells (EPCs)126. By using an 
exogenous CXCR2 C-tail peptide or DNA construct (containing CXCR2 PDZ motif), 
CXCR2-mediated intracellular calcium mobilization in EPC, EPC in vitro migratory 
responses and neovessel formation, and EPC in vivo angiogenesis were significantly 
impaired. Our findings not only identified the existence and biological functions of the 
CXCR2 complex, but also revealed the therapeutic potential of targeting PDZ-mediated 
CXCR2 macromolecular complex in inflammation, cancer, and angiogenesis. 
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Although the scaffolding proteins have been demonstrated to regulate the CXCR2 
signalings in diseases; however, it has been proved that eradication of the scaffolding 
proteins would not simply achieve the desired inhibitory effect in disease conditions. For 
example, although the β-arrestin 2 plays crucial roles in mediating CXCR2-
signaling119,120, eradication of β-arrestin 2, unexpectedly, caused enhanced CXCR2 
signaling and functional endpoints in vitro and in vivo127. This warrants the necessity of 
unveiling more structural details of the interaction between CXCR2 and its interacting 
partners to develop new therapeutic strategies. Therefore, we further investigated the 
structural basis of the NHERF1 PDZ1 domain in complex with the C-terminal sequence 
of CXCR2 at 1.1 Å resolution128. We not only determined that the positions 0 and -2 of 
the PDZ motif (position 0 referring to the extreme C-terminal residue) possess the ability 
to form networks of hydrogen bonds and hydrophobic interactions with NHERF1-PDZ1 
domain, which are responsible for the stabilization and specificity of PDZ1-CXCR2 
interaction, but also observed that the interaction between NHERF1-PDZ1 and CXCR2 
at position -1 and -3 of the PDZ motif are very different from other PDZ1-PDZ motif 
interactions (i.e. PDZ1-CFTR, PDZ1- β2AR, and PDZ1-PDGFR). Specifically, the 
orientation, the rotameric states, and binding preference of His29 and Arg40 in the 
NHERF1 PDZ1 domain is very different in PDZ1-CXCR2 interaction than in PDZ1-
CFTR, PDZ1-β2AR, and PDZ1-PDGFR interactions. The unveiled structural basis 
suggests that even though both -1 and -3 residues in PDZ motif were less stringently 
specified than 0 and -2 residues in the PDZ domains, they could still interact with a few 
key residues in the PDZ motif-binding pocket specifically, which endow -1 and -3 
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residues with critical roles in PDZ motif recognition and selection within a network of 
NHERF-scaffolded interactions. Also, the conformation and rotameric states of the 
residues in the PDZ motif-binding pocket are also important in different side chain 
recognition of the PDZ motif and specific interaction. Our most recent study has also 
demonstrated the presence of the substantial structural flexibility in the PDZ1 peptide-
binding pocket, which provides potential strategies for drug design against the NHERF1 
PDZ1 domain129. 
 
Our findings of the functional significance and therapeutic potential of the interaction 
between CXCR2 and NHERF1 in inflammation, tumorigenesis, and angiogenesis may 
be valuable in the development of innovative strategies for targeted drug discovery. 
However, the complexity of the NHERF1 interaction network and its versatile roles in 
regulation of many cellular processes essential to normal physiology130,131 poses a 
challenge for designing CXCR2 inhibitors that are specific to the CXCR2-NHERF1 
interaction without cross-inhibiting any of the other NHERF1-coordinated signaling 
events. Therefore, the specificity and selectivity of the novel CXCR2 inhibitors targeting 
on the CXCR2-NHERF1 interaction is dependent upon the understanding of the 
structural features that how the PDZ motif and critical residues in PDZ binding pocket 
work in coordination to determine the PDZ motif recognition and specificity of the 
interaction, and upon the exploitation of these features to differentiate CXCR2 from 
other NHERF1-interacting proteins. Further structural studies regarding identification of 
critical residues, from both PDZ motif and PDZ binding pocket, which are responsible 
for CXCR2 recognition, would be beneficial to design novel inhibitors that disrupt 
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CXCR2-NHERF1 interaction specifically without affecting other NHERF1 interaction and 
NHERF1-scaffolded signaling complex. 
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Chapter II 
CXCR2 Macromolecular Complex in Pancreatic Cancer 
© 2013 Neoplasia Press (Translational Oncology) 
 
2.1 Introduction 
2.1.1 Overview of Pancreatic Cancer 
Pancreatic cancer, the most lethal malignancy of the gastrointestinal tract with 5-year 
survival rates of less than 5%, is the fourth leading cause of cancer-related deaths in 
both men and women in the United States132. The most common type of pancreatic 
cancer is pancreatic ductal adenocarcinoma (PDAC). Chemoresistance, early 
metastases and late clinical presentation in this incurable human malignancy result in 
no effective methods for early prognosis as well as a lack of effective systemic therapies 
with reduced side effects133,134. Therefore, a more comprehensive understanding of the 
biology of PDAC and the mechanisms/factors that promote invasion and tumor growth 
may help identify new molecular targets for the development of diagnostics and/or 
therapeutics of pancreatic cancer. 
 
2.1.2 Biological Axis of CXCR2 in Pancreatic Cancer 
CXC-chemokine receptor 2 (CXCR2) is the cognate receptor for the CXC-chemokines, 
CXCL1 ~ 3 and CXCL5 ~ 89. The CXC-chemokine/CXCR2 signaling has been reported 
to promote malignant cancer progression in many cancer types including pancreatic 
cancer135-139. It has been documented that the elevated expression of CXCL5 and 
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CXCL8 is correlated with poor differentiation, histopathologic grade and advanced 
clinical grade pancreatic adenocarcinomas in patients74,140. Recent studies also suggest 
that CXCR2 is expressed in various PDAC cell lines141-144 and is primarily involved in 
enhancing the proliferation and survival of cancer cells via the autocrine and/or 
paracrine effect74,141,144. More importantly, increased expression of CXCR2 and its 
ligands has been shown in higher grades and stages of pancreatic adenocarcinomas in 
patients 63,140, indicating that CXCR2 is involved in the exacerbation of tumors and could 
be a promising target for developing selective and effective treatments for pancreatic 
cancer. As a G-protein coupled receptor (GPCR), CXCR2 couples to the pertussis 
toxin-sensitive Gi proteins to stimulate phosphatidylinositide-specific phospholipase C 
(PLC) activities145. Agonist-induced activation of PLC-β, one of the six families of PLC 
isozymes, catalyzes the hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2), 
generating 1, 2-diacylglycerol (DAG) and inositol-1, 4, 5-trisphosphate (IP3) which 
activates PKC isoforms and triggers the release of Ca2+ from internal sources, 
respectively.  
 
2.1.3 PDZ proteins and PDZ domain-mediated protein-protein interaction 
PDZ (PSD-95/DlgA/ZO-1) domains are ubiquitous protein-protein recognition modules 
that form peptide-binding pockets and generally mediate physical interaction with the 
carboxyl termini of a wide variety of proteins (such as membrane receptors, ion channel, 
etc.) that terminate in consensus binding motifs (referred to as PDZ motif)146,147. PDZ 
domains are important to nucleate the formation of compartmentalized multi-protein 
complexes that are critical for efficient and specific  cell signaling148. These domains are 
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able to specifically recognize and bind short carboxyl-terminal peptides of a variety of 
proteins (membrane receptors, ion channel families, etc.). The specific C-terminal 
sequence motifs are usually 4 ~ 5 residues in length, and are referred to as PDZ motifs. 
The nomenclature for the PDZ motif is described as follows: the extreme C-terminal 
residue is referred to as the P0 residue; subsequent residues towards the N-terminal are 
termed P
-1, P-2, P-3, etc. Comprehensive peptide library screens suggest that P0 and P-2 
residues at the C-terminus of the membrane receptors are most critical for recognition 
and physical interaction between membrane receptors and PDZ domain-containing 
proteins (also referred to as PDZ scaffold proteins or PDZ proteins)149. In general, 
particular hydrophobic P0 residues, such as Valine (V) or Leucine (L), are preferred, 
although sequence variations of PDZ domains could change the size and shape 
preference150,151. Also, variations in the P
-2 binding pocket result in distinct preferences 
for hydroxylated, charged or hydrophobic amino acids. In class I PDZ domains, 
hydroxylated side chain of either a Serine (S) or Threonine (T) is favored at P
-2  due to a 
specific hydrogen bond that is formed from a histidine residue152. 
 
A variety of PDZ domain-containing proteins (also referred to as PDZ scaffold/adaptor 
proteins) have been reported to nucleate the formation of compartmentalized multi-
protein complexes that are critical for efficient and specific cell signaling153-157. Some 
PDZ scaffold proteins, such as Na+/H+ exchange regulatory factors (NHERF1 & 
NHERF2) and PDZ domain containing 1 (PDZK1), preferentially associate with the 
surface membrane of epithelial cells and interact with membrane receptors and their 
downstream effectors. PLC-β is one of the downstream effectors for GPCR signaling, 
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and it has been reported to specifically bind with the PDZ scaffold proteins via PDZ-
based interaction since all PLC-β isoforms possess consensus PDZ motifs, -X-S/T-X-
L/V-COOH (X represents any amino acid), at their carboxyl termini158-161. Therefore, the 
specificity of agonist-induced PLC-β activation and subsequent intracellular signaling 
might be dependent upon the specific interactions of PLC-β with particular PDZ scaffold 
proteins162. Similar to PLC-β isoforms, CXCR2 also possesses a consensus PDZ motif 
(-S-T-T-L-COOH) at its carboxyl termini. Previous studies by us and others have 
demonstrated that the PDZ motif of CXCR2 is involved in the regulation of intracellular 
signaling and cell functions in neutrophils163 as well as post-endocytic sorting and 
cellular chemotaxis in CXCR2-overexpressing HEK293 cells123. Hence, the PDZ motif of 
CXCR2 can, theoretically, mediate potential interaction with certain PDZ scaffold 
proteins, which subsequently binds relevant downstream effectors, forming multi-protein 
macromolecular complexes. However, the molecular mechanism(s) as to how this 
potential CXCR2 macromolecular complex are formed and/or regulated, as well as what 
role the CXCR2 complex might play in PDAC growth and progression have not been 
determined. 
 
2.2 Materials and Methods 
2.2.1 Antibodies and Reagents 
Anti-human CXCR2, NHERF1, PLC-β3, and GAPDH antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human chemokines, 
CXCL8/IL-8, CXCL5/ENA-78, and CXCL1/GROα, were obtained from ProSpec-Tany 
Technogene (East Brunswick, NJ). Growth factor reduced Matrigel matrix, glutathione 
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agarose beads and Transwell inserts were purchased from BD Bioscience (Franklin 
Lakes, NJ). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and 
protease inhibitors (Aprotinin, Leupeptin, Pepstatin A, and phenylmethylsulfonyl fluoride) 
were purchased from Sigma-Aldrich (St. Louis, MO). Human CXCR2 C-tail peptides 
(biotin-conjugated at N-terminus): wild-type “WT” (biotin-FVGSSSGHTSTTL), PDZ motif 
deletion mutant “∆TTL” (biotin-FVGSSSGHTS) and PDZ motif mutant “AAA” (biotin-
FVGSSSGHTSAAA) were synthesized by Genemed Synthesis Inc. (San Antonio, TX) 
and used as reported before163. ChariotTM peptide/protein delivery reagent was 
purchased from Active Motif (Carlsbad, CA). S-protein agarose and streptavidin beads 
were purchased from Novagen/EMD Millipore (Billerica, MA). Coomassie Brilliant Blue, 
bradford protein assay kit and Western Blot apparatus were obtained from Bio-Rad 
Laboratories, Inc. (Hercules, CA). Polyacrylamide gel for Western Blot analysis was 
purchased from Genscript Corp. (Piscataway Township, NJ). Fetal bovine serum (FBS) 
and antibiotics, Ampicillin sodium salt, Kanamycin sulfate, and Puromycin 
dihydrochloride, were purchased from Fisher Scientific (Pittsburgh, PA). Penicillin and 
Streptomycin were purchased from Invitrogen/Life Technologies (Carlsbad, CA). The 
plasmid pcDNA3.1(+)-FLAG-PLC-β3 was obtained from the laboratory of Dr. Theresa M. 
Filtz (Oregon State University), and used for construct generation was described 
before164.  Bacterial stock of plamid DNA of pGEX-4T-1-NHREF1, pGEX-4T-1-NHERF2, 
pGEX-4T-1-PDZK1, pGEX-4T-1-NHERF1-PDZ1, pGEX-4T-1-NHERF1-PDZ2, and 
pGEX-4T-1-PDZ1&2 were obtained from Dr. Anjaparavanda P. Naren’s laboratory at 
The University of Tennessee Health Science Center (current institution: Cincinnati 
25 
 
 
 
Children’s Hospital Medical Center). All the pGEX-4T-1 plasmids were used to generate 
purified proteins with GST tag (see section 2.2.3).  
 
2.2.2 Bacterial Strains, plasmid constructions, and mutagenesis 
E. coli strain NovaBlue GigaSinglesTM Competent cells (genotype: endA1 hsdR17(rk12-
mk12
+)supE44thi-1 recA1 gyrA96relA1 lacF’[proA+B+lacqZ∆M15::Tn10(TcR)], Novagene/ 
EMD Millipore, Billerica, MA) was used for molecular cloning. Strain DH5αTM (genotype: 
F– Φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1) was obtained from Dr.  Anjaparavanda P. Naren’s 
laboratory at The University of Tennessee Health Science Center, and was used for 
molecular cloning. E.coli strain BL21 (DE3) (genotype: [F- ompT hsdSB (rB-mB-) gal dcm 
(DE3 [lacl lacUV5-T7 gene1 ind1 Sam7 nin5; New England Biolabs] was used for 
protein expression and purification. 
 
Plasmid vector, pGEX-4T-1, which contains a Glutathione S-transferase tag (GST-tag) 
in frame and upstream of the multiple cloning site, was purchased from GE Healthcare 
(formerly Amersham Biosciences). Plasmid vector, pET-41, which contains a GST-His-
S tag in frame and upstream of the multiple cloning site, was purchased from Novagen 
/EMD Millipore (Billerica, MA). Plasmid vectors, pET-30 and pTriEx-4, which both 
contain His-S tag in frame and upstream of the multiple cloning site, were purchased 
from Novagen/EMD Millipore (Billerica, MA). Plasmid vectors, pGEX-4T-1, pET-30, and 
pET-41, were used to generate purified proteins fused with GST tag, His-S tag, and 
GST-His-S tag, respectively. 
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The construct, pcDNA3.1(+)-3HA-CXCR2 (full length), was purchased from Missouri 
University of Science and Technology cDNA Resource Center (Prod# CXCR20TN00, 
Rolla, MO), and used as a template to create the following constructs by ligation 
independent cloning (LIC) kit from Novagen/EMD Millipore (Billerica, MA): pET-30-
hCXCR2-C-tail (Wild-type), pET30-hCXCR2-C-tail (PDZ motif deletion), pET-30-
hCXCR2-C-tail (PDZ motif mutation), pET-41-hCXCR2-C-tail (Wild-type), pET-41-
hCXCR2-C-tail (PDZ motif deletion), pET41-hCXCR2-C-tail (PDZ motif deletion), 
pTriEx4-hCXCR2-C-tail (Wild-type), pTriEx4-hCXCR2-C-tail (PDZ motif deletion), 
pTriEx4-hCXCR2-C-tail (PDZ motif mutation). The primers used for plasmid 
constructions were summarized in Table 2.1. The PCR conditions used were as follows: 
1 minute denaturation at 95°C, 35 amplification cyc les with an annealing temperature of 
55°C, and final extension of 72°C for 5 minutes. PC R products were run on a 1.5% DNA 
agarose gel. PCR products of the correct size were excised from the gel, extracted and 
purified using Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, WI). 
The plasmids were purified by the PureYieldTM DNA preparation system (Promega). 
 
The construct pcDNA3.1(+)-FLAG-PLC-β3-FL that encodes the full length of human 
PLC-β3, was used as a template to create the following PLC-β3 constructs by ligation 
independent cloning (LIC) kit from Novagen/EMD Millipore (Billerica, MA): pET-30-
hPLC-β3-C-tail (Wild-type), pET30-hPLC-β3-C-tail (PDZ motif deletion), pET-30-hPLC-
β3-C-tail (PDZ motif mutation), pET-41-hPLC-β3-C-tail (Wild-type), pET-41-hPLC-β3-C-
tail (PDZ motif deletion), pET41-hPLC-β3-C-tail (PDZ motif deletion), pTriEx4-hPLC-β3-
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C-tail (Wild-type), pTriEx4-hPLC-β3-C-tail (PDZ motif deletion), pTriEx4-hPLC-β3-C-tail 
(PDZ motif mutation). The primers used for plasmid constructions were also 
summarized in Table 2.1. All the plasmids were sent for DNA sequencing (Genewiz, 
South Plainfield, NJ) to ensure the accurate DNA sequence. 
 
2.2.3 Protein Expression and Purification 
Aforementioned pET41 constructs (GST-His-S-tagged) and pET30 constructs (His-S-
tagged) were transformed into E. Coli BL21 (DE3) cells for protein expression. A heat-
shock method was used in bacterial transformation. Briefly, a sudden increase of 
temperature (42oC for 30s) creates pores in the plasma membrane of the bacterial 
competent cells, allowing the plasmid DNA entering the competent cells. A rich medium, 
S.O.C. medium, was used for the recovery of the E. Coli competent cells, maximizing 
the transformation efficiency of competent cells. SOC medium contains 0.5% Yeast 
Extract, 2% Tryptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, and 
20mM glucose. 
GST-tagged proteins were purified from transformed E. Coli BL21 (DE3) bacteria. A 5ml 
overnight culture in Luria-Bertani broth medium (Fisher Scientific, Pittsburgh, PA) was 
made from a glycerol stock. The overnight culture was diluted into the large scale LB 
Broth medium (500ml), and culture was grown in LB Broth medium with 15µg/ml 
kanamycin at 37oC with constant shaking until it reached an OD600 of 0.6~ 1.0. The 
protein expression was induced using isopropyl β-D-1-thiogalactopyranoside (IPTG) 
with 200µM final concentration at 37 oC with constant shaking for 3hrs. Bacteria were 
pelleted by centrifugation at 5,000g for 15min. Bacterial pellets were frozen at -80 oC 
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Table 2.1 Primers used in this study 
Plasmid Sequence 
pET30/41/pTriEx4-CXCR2-C-
tail (WT) 
Forward (5’) GACGACGACAAGATGTTCATT
GGCCAGAAG 
Reverse (5’) GAGGAGAAGCCCGGTTTAGA
GAGTAGTGGAAGT 
pET30/41/pTriEx4-CXCR2-C-
tail (∆TTL) 
Forward (5’) GACGACGACAAGATGTTCATT
GGCCAGAAG 
Reverse (5’) GACGGATCCTTAGAGAGTAGT
GGA 
pET30/41/pTriEx4-CXCR2-C-
tail (AAA) 
Forward (5’) CAGGGCACACTTCCGCTGCTG
CCTAAACCGGGCTTCTCC 
Reverse (5’) GGAGAAGCCCGGTTTAGGCA
GCAGCGGAAGTGTGCCCTG 
pET30/41/pTriEx4-CXCR2-C-
tail (ATA) 
Forward (5’) CAGGGCACACTTCCGCTACTG
CCTAAACCGGGCTCTCC 
Reverse (5’) GGAGAAGCCCGGTTTAGGCA
GTAGCGGAAGTGTGCCCTG 
pET30/41/pTriEx4-hPLC-β3-
full-length (WT) 
Forward (5’) GACGACGACAAGATGGCGGG
CGCCCAG 
Reverse (5’) GAGGAGAAGCCCGGTTAGAG
CTGCGTGTTCTC 
pET30/41/pTriEx4-hPLC-β3-
full-length (∆TTL) 
Forward (5’) GACGACGACAAGATGGCGGG
CGCCCAG 
Reverse (5’) GAGGAGAAGCCCGGTTAGTTC
TCCTCCTGGCTC 
pET30/41/pTriEx4-hPLC-β3-
C-tail (WT) 
Forward (5’) GACGACGACAAGATGGTCAAC
TCCATCCGT 
Reverse (5’) GAGGAGAAGCCCGGTTAGAG
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CTGCGTGTTCTC 
pET30/41/pTriEx4-hPLC-β3-
C-tail (∆TTL) 
Forward (5’) GACGACGACAAGATGGTCAAC
TCCATCCGT 
Reverse (5’) GAGGAGAAGCCCGGTTAGTTC
TCCTCCTGGCTC 
pET30/41/pTriEx4-hPLC-β3-
C-tail (AAA) 
Forward (5’) GACGACGACAAGATGGTCAAC
TCCATCCGT 
Reverse (5’) GAGGAGAAGCCCGGTCAAGC
AGCAGCGTTCTC 
Human CXCR2 (Reverse-
transcriptase PCR) 
Forward (5’) AACATGGGCAACAATACAGCA 
Reverse (5’) TGAGGACGACAGCAAAGATG 
HumanPLC-β3 (Reverse-
transcriptase PCR) 
Forward (5’) AGTTCCAGAACAGACAGGTG 
Reverse (5’) TTCTTATGCTTGTCCCTCAT 
Human NHERF1 (Reverse-
transcriptase PCR) 
Forward (5’) GAGACCAAGCTGCTGGTG 
Reverse (5’) GGCCAGGGAGATGTTGAAG 
Human GAPDH (Reverse-
transcriptase PCR) 
Forward (5’) ATGTTCCAGGAGCGAGATCC 
Reverse (5’) ACCACTGACACGTTGGCAGT 
hNHERF1-pLKO.1-shRNA1 Forward (5’) CCGGCAGGGAAACTGACGAG
TTCTTCTCGAGAAGAACTCGT
CAGTTTCCCTGTTTTTG 
Reverse (5’) AATTCAAAAACAGGGAAACTG
ACGAGTTCTTCTCGAGAAGAA
CTGGTCAGTTTCCCTG 
hNHERF1-pLKO.1-shRNA2 Forward (5’) CCGGCAGAAGGAGAACAGTC
GTGAACTCGAGTTCACGACTG
TTCTCCTTCTGTTTTTG 
Reverse (5’) AATTCAAAAACAGAAGGAGAA
CAGTCGTGAACTCGAGTTCAC
GACTGTTCTCCTTCTG 
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overnight, and resuspended in lysis buffer (Tris base, NaCl) supplemented with 
protease inhibitors (aprotinin [1µg/ml], leupeptin [1µg/ml], pepstatin [1µg/ml], 
phenylmethylsulfonyl fluoride (PMSF) [500µM], and Lysozyme [100µg/ml]). The 
bacterial pellets were sonicated on ice, and allowed to mix at 4oC for 30 minutes. 
Subsequently, 10% Triton-X was added to the suspension and LYallowed to mix at 4oC 
for 30 minutes. The bacterial debris was then pelleted down by centrifugation at 
27,000g for 20 minutes at 4oC. Glutathione agarose beads (50% slurry) were then 
added to the cleared supernatant and allowed to mix for 2 hour at 4oC. Glutathione 
agarose beads were pelleted down by centrifugation at 800g and washed by TBS 
(25mM Tris, 137mM NaCl, 2.7mM KCl, PH = 7.4) for 5 times. Proteins were eluted from 
the glutathione agarose beads using 50mM glutathione (PH 7.5), and the excessive 
glutathione was subsequently dialyzed away by centrifugation in the Amicon® 
Centrifugal Filters (Molecular Weight Cut-Off: 3kDa, EMD/Millipore, Billerica, MA). The 
concentration of purified proteins was estimated using the Braford protein estimation 
assay (Bio-Rad). A 20µl sample of the protein was eluted using Laemmli sample buffer 
and run on a polyacrylamide gel to visualize the quantity and quality of the purified 
protein. Laemmili sample buffer contains 60mM Tris-base, 10% (v/v) glycerol, and 2% 
SDS (electrophoresis grade). 
 
His-S-tagged proteins were purified using a similar protocol with a few changes. Cobalt 
beads (50% slurry) were added to the cleared supernatant and allowed to mix at 4oC for 
30 minutes instead of glutathione agarose beads. Proteins were eluted from the cobalt 
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beads using His binding buffer (500mM NaCl, 80mM Tris-base, 25mM Imidazole, 
PH=7.4) 
 
2.2.4 Cell Culture 
Human pancreatic ductal adenocarcinoma cell lines (PANC-1, MIA PaCa-2, AsPC-1, 
BxPC-3 and HPAC) and Human Embryonic Kidney 293 cells (HEK293) were obtained 
from American Type Culture Collection (Manassas, VA). Normal human pancreatic duct 
epithelial (HPDE) cells, pancreatic cancer cell lines, Colo357 and L3.6pl, were obtained 
from Dr. Paul J Chiao at the University of Texas MD Anderson Cancer Center (Houston, 
TX). PDAC cells (PANC-1, MIA PaCa-2, HPAC, AsPC-1, BxPC-3, Colo357, and L3.6pl) 
and HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium (Thermo 
Scientific, Rockford, IL) containing 4.5g/l D-glucose and L-glutamine supplemented with 
10% fetal bovine serum (FBS), 100 units/ml penicillin, ad 100µg/ml streptomycin at 
37oC in humidified air with 5% CO2. HPDE cells were cultured in keratinocyte serum-
free medium (Invitrogen/Life Technologies, Carlsbad, CA) supplemented with 5ng/ml 
epidermal growth factor, 50µg/ml bovine pituitary extract, 100 units/ml penicillin, ad 
100µg/ml streptomycin. PANC-1, MIA PaCa-2, AsPC-1, BxPC-3 and HPAC were 
derived from different pancreatic cancer patients with adenocarcinoma of the pancreas. 
All the PDAC cells were subcultured as a ratio of 1:6 ~ 1:8, and cryopreserved by the 
complete medium with 5% (v/v) DMSO in liquid nitrogen. Human Umbilical Vein 
Endothelial cells (HUVEC) were obtained from American Type Culture Collection 
(Manassas, VA). HUVEC cells were cultured in EBM-2 medium supplemented with 5% 
FBS, human recombinant Epidermal Growth Factor, hydrocortisone, human Fibroblast 
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Growth Factor Basic with heparin, Vascular Endothelial Growth Factor, human 
recombinant Insulin-like Growth Factor, Ascorbic Acid, and Gentamicin (Amphotericin-B) 
(Fisher Scientific, Pittsburgh, PA). The HUVEC cells were cryopreserved by the 70% 
(v/v) complete medium, 20% (v/v) FBS, and 10% (v/v) DMSO. 
 
2.2.5 DNA Transfection 
LipofectamineTM 2000 transfection reagent (Invitrogen/Life Technologies, Carlsbad, CA) 
was used for the DNA transfection. Briefly, cells were seeded on tissue culture dishes 
until 70% ~ 80% confluency. On the transfection day, the cells were washed and 
cultured with basal medium (without serum and antibiotics). The transfection complex 
was set up in two tubes. The first tube contained the Opti-MEM medium (Invitrogen/Life 
Technologies, Carlsbad, CA) and DNA, and the second tube contained Opti-MEM 
medium with LipofectaminTM 2000 transfection reagent based on the optimum condition 
provided by the manufacturer. The transfection complex was then added to the cell 
culture dishes, and incubated at 37oC for 6 hours. Then, the medium was cultured in the 
complete growth medium for 24 ~ 48 hours for the studies. 
 
2.2.6 Western Blot Analysis 
Cells were lysed in lysis buffer (50 mM Tris - pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 
0.5% sodium deoxycholate, 0.1% SDS) supplemented with a mixture of protease 
inhibitors (containing 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml 
pepstatin and 1 µg/ml leupeptin). Protein concentration of the cleared supernatant 
(17,000 x g, 15 min) was estimated by Bradford protein assay (Bio-Rad). Proteins were 
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eluted in Laemmli sample buffer containing β-mercaptoethonal, separated by SDS-
PAGE (7.5% or 4–15%), and immunoblotted using indicated antibodies. The signal was 
detected by SuperSignal® West Pico (or Femto) substrate (Thermo Scientific, Rockford, 
IL). The blots were visualized and recorded using a BioSpectrum 500 Imaging system 
(UVP, Upland, CA). The images were analyzed using ImageJ software (National 
Institutes of Health, Bethesda, MD).  
 
2.2.7 GST Pull-down Assay 
GST pull-down assay was performed as previously described163. Briefly, fresh PDAC 
cells were lysed in binding buffer (PBS + 0.2% Triton X-100, supplemented with a 
mixture of protease inhibitors (aprotinin [1µg/ml], leupeptin [1µg/ml], pepstatin [1µg/ml], 
phenylmethylsulfonyl fluoride (PMSF) [500µM]). Cell lysate was mixed at 4oC for 15 
minutes and centrifuged at 17,000g for 15 minutes to retrieve the cleared supernatant. 
The cleared supernatant was equally mixed with GST alone or various GST-PDZ fusion 
proteins (GST-NHERF1, GST-NHERF2, or GST-PDZK1) at 4ºC for 2 hrs. The mixture 
was pulled down by glutathione agarose beads (BD Biosciences) at 4ºC overnight. The 
glutathione agarose beads were centrifuged at 700g for 1 minute and washed three 
times with binding buffer. The proteins were eluted in Laemmli sample buffer containing 
β-mercaptoethonal (5%). The eluents were separated by SDS-PAGE, transferred to a 
PVDF membrane by Western Blot apparatus (Bio-Rad) and immunoblotted with anti-
CXCR2 or anti-PLC-β3 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
2.2.8 Pair-wise Binding Assay 
34 
 
 
 
Purified GST-NHERF1 was mixed with various purified His-S-PLC-β3 C-tail fragments 
(WT, or PDZ motif mutants, ∆TQL, AAA), or CXCR2 C-tail peptides (biotin-conjugate at 
N-terminus; WT, or PDZ motif mutants, ∆TTL, AAA) in binding buffer (PBS + 0.2% 
Triton X-100 + protease inhibitors (aprotinin [1µg/ml], leupeptin [1µg/ml], pepstatin 
[1µg/ml], phenylmethylsulfonyl fluoride (PMSF) [500µM])) at 22-24ºC for 1 hr. The 
mixtures were incubated with S-protein agarose (for His-S-tagged fusion proteins), or 
streptavidin beads (for biotin-conjugated peptides) for 2 hrs. The beads were 
centrifuged at 700g for 1 minute and washed three times with binding buffer. The bound 
proteins were eluted with Laemmli sample buffer containing β-mercaptoethonal (5%). 
The eluents were resolved and separated by SDS-PAGE, transferred to a PVDF 
membrane by Western Blot apparatus (Bio-Rad) and immunblotted with anti-NHERF1 
antibody (Santa Cruz Biotechnology). 
 
2.2.9 Macromolecular Complex Assembly Assay 
Purified His-S-tagged CXCR2 C-tail fragments (WT, PDZ motif mutants ∆TTL or AAA) 
or His-S-tagged PLC-β3 C-tail fragments (WT, PDZ motif mutants ∆TQL or AAA) were 
mixed with GST-NHERF1 (or GST alone) in 200 µl of binding buffer (PBS + 0.2% Triton 
X-100 + protease inhibitors (aprotinin [1µg/ml], leupeptin [1µg/ml], pepstatin [1µg/ml], 
phenylmethylsulfonyl fluoride (PMSF) [500µM])), and the complex was pulled down with 
S-protein agarose. This step is also referred to as pair-wise binding as described above. 
The dimeric complex was then mixed with the lysates of PDAC cells expressing 
endogenous full-length PLC-β3 and CXCR2 for 3 hrs at 4°C. The S-protein agarose  
were centrifuged at 700g for 1 minute and washed extensively with binding buffer. The 
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bound proteins were then eluted by Laemmli sample buffer containing β-
mercaptoethonal (5%), resolved and separated by SDS-PAGE, transferred to a PVDF 
membrane by Western Blot apparatus (Bio-Rad) and immunoblotted using anti-PLC-β3 
or anti-CXCR2 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
2.2.10 Co-Immunoprecipitation Assay 
A co-immunoprecipitation kit (Thermo Scientific/Pierce, Rockford, IL) was used to 
immobilize the normal IgG control and anti-CXCR2 IgG to the resin according to 
manufacturer’s instruction. PDAC cells were lysed in binding buffer (PBS + 0.2% Triton 
X-100 + protease inhibitors (aprotinin [1µg/ml], leupeptin [1µg/ml], pepstatin [1µg/ml], 
phenylmethylsulfonyl fluoride (PMSF) [500µM])), and cleared cell lysates (17,000 × g, 
15 min) were processed for co-immunoprecipitation (co-IP) as reported before155,163. 
The co-precipitated protein complex was resolved and separated by SDS-PAGE, and 
probed for NHERF1 and PLC-β3. For the reverse co-IP, anti-PLC-β3 IgG was used to 
immunoprecipitate the complex. The co-precipitated protein complex was separated by 
SDS-PAGE and probed for NHERF1 and CXCR2. The signal was detected by 
SuperSignal® West Pico (or Femto) substrate (Thermo Scientific, Rockford, IL). 
 
2.2.11 Cell Proliferation Assay 
Cell proliferation was assessed by MTT assay as reported before74. In brief, PDAC cells 
were seeded in 96-well plates (7 × 103 cells per well) and allowed to adhere overnight. 
Then, the cells were fed with serum-free fresh media with or without 100 ng/mL of 
CXCR2 ligands (CXCL1, CXCL5 or CXCL8). After indicated growth periods, cells were 
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incubated with 20µl of MTT solution (1 mg/ml) at 37ºC for 3.5 hrs and then incubated 
with MTT solvent (4 mM HCl, 0.1% Nonidet P-40 in isopropanol) under constant mixing 
protected from light for 15 min at 22-24ºC. Spectrophotometric absorbance of the 
samples at 590 nm was determined by a microplate reader (Bio-Rad). In parallel, 
Colo357 and HPAC cells were transfected with various pTriEx4 plasmids (vector alone, 
CXCR2 C-tail ∆TTL, or CXCR2 C-tail WT) or delivered with CXCR2 C-tail peptides (WT 
or ∆TTL) for 24-48 hours prior to the MTT assay as indicated.  
 
Another peptide inhibitor targeting the interaction between CXCR2 and NHERF1, 
EF1060, was synthesized in Dr. Spaller’s laboratory (Dartmouth College, NH). EF1060 
is myristoylated at N-terminus and bears the last eight amino acids of the C-terminal 
sequence of CXCR2 (N-myristoyl-SGHTSTTL), as shown in Figure 2-10 A. MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was purchased from Sigma-
Aldrich (St Louis, MO). EF1060 was dissolved in DMSO. Cell proliferation was 
assessed by MTT assay as reported before74. In brief, MIA PaCa-2 cells were seeded in 
96-well plates (7 × 103 cells per well) and allowed to adhere overnight. The cells were 
treated with EF1060 with control groups (DMSO and non-treatment). After indicated 
growth periods, cells were incubated with 20 µl of MTT solution (1 mg/ml) at 37ºC for 
3.5 hrs and then incubated with MTT solvent (4 mM HCl, 0.1% Nonidet P-40 in 
isopropanol) under constant mixing protected from light for 15 min at 22 ~ 24ºC. 
Spectrophotometric absorbance of the samples at 590 nm was determined by a 
microplate reader (Bio-Rad). 
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2.2.12 Cell Invasion Assay 
PDAC cells were plated at a density of 1.5 × 105 cells per well in 24-well plate. Cells 
were transfected with various pTriEx4 plasmids (vector alone, CXCR2 C-tail ∆TTL, or 
CXCR2 C-tail WT). After 48 hrs’ incubation, in vitro invasion assay was performed using 
Transwell inserts (BD Biosciences) with 8.0 µm pore size. Briefly, 1 × 105 transfected 
PDAC cells were suspended in serum-free medium and seeded onto the Transwell 
inserts pre-coated with diluted (1:3) Matrigel. The Transwell inserts were then placed 
into 24-well plates filled with the same medium containing 100 ng/ml CXCL8. After 16 
hrs’ incubation, the upper surface of the Transwell inserts were wiped with a cotton 
swab and the invaded cells were fixed and stained with Diff-Quick stain (IMEB Inc., San 
Marcos, CA). The number of invading cells was counted under an inverted microscope 
(× 50) in 3 randomly selected fields per well. The data were analyzed by ImageJ 
software (National Institutes of Health, Bethesda, MD) and Microsoft Excel software. In 
separate experiments, PDAC cells were delivered with CXCR2 C-tail peptides (WT or 
∆TTL) for 24 hrs, and the cell invasion was assessed as described above. 
 
2.2.13 Pancreatic Cancer-induced angiogenesis of endothelial cells 
The PANC-1 cells were transfected with various pTriEx4 plasmids (vector alone, 
CXCR2 C-tail ∆TTL, or CXCR2 C-tail WT) or delivered with CXCR2 C-tail peptides (WT 
or ∆TTL) for 24-48 hrs prior to the angiogenesis assay. The transfected PANC-1 cells 
were seeded onto the Transwell inserts with 0.4µm pore size, and allowed to adhere for 
3hrs. Growth Factor Reduced Matrigel (Fisher Scientific, Pittsburgh, PA) was used to 
mimic the extracellular matrix, and was diluted with the basal EBM-2 medium, and 
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allowed to form the gel in the 24-well plates for 2 hours at 37oC. HUVEC cells were 
treated with basal EBM-2 medium (serum- and growth factors-free) for 3 hours prior to 
the angiogenesis assay, and were seeded onto the diluted Matrigel. Then, the 
transfected PANC-1 cells on the Transwell inserts were placed onto the 24-well plates 
containing the HUVEC cells. After indicated periods, tube formation was examined 
under the microscope. The lengths of the tube formed by HUVEC cells were measured 
by ImageJ software (National Institutes of Health, Bethesda, MD), and analyzed by 
Microsoft Excel software. 
 
2.2.14 Xenografts of Human Pancreatic Cancer cells in Immunodeficient Mice  
Three GFP-tagged AAV2 constructs, AAV2/2CMV-GFP, AAV2/2CMV-GFP-CXCR2 C-
tail ∆TTL and AAV2/2CMV-GFP-CXCR2 C-tail WT (customized by the Gene Transfer 
Vector Core, University of Iowa) were used to transduce HPAC cells. CB17 severe 
combined immunodeficient (CB17-SCID) mice (female, 4 ~ 6 weeks old) were randomly 
divided into four groups (n = 10-12), and each mouse received 200 µl serum-free 
DMEM containing 3 × 106 HPAC cells (transduced or non-transduced) subcutaneously 
in the unilateral flank area. The mice were subjected to measurement of subcutaneous 
tumors every other day and monitored for changes in body weight and other side 
effects. Tumor volume was calculated by the formula (L × W2)/2, where L and W are the 
tumor length and width (in mm), respectively. To avoid severe discomfort in the control 
group, animals were euthanized after 4 weeks. Tumor tissues were harvested for 
histological analysis and immunohistochemical staining. Tumor volume in SCID mice 
was plotted against time, and the final tumor weights were measured after the mice 
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were euthanized. All the animal studies were accomplished under the protocol approved 
by Wayne State University Institutional Animal Care and Use Committee. 
 
2.2.15 Immunohistochemistry and Quantification of Proliferation Index  
Tumor tissue from the xenografts was fixed by 4% paraformaldehyde (PH = 7.5) and 
embedded within paraffin. Paraformaldehyde-fixed and paraffin-embedded sections (5 
µm) were stained with Ki-67 antibody (Ventana Medical Systems, Tucson, AZ) as 
reported165. Results were expressed as percentage of Ki-67 positive cells per 200 x 
magnification (Ki-67+ cell number/total cell number). A total of 10 sections from each 
experimental group were examined by Zeiss Axiophot epifluorescence microscope (Carl 
Zeiss) and analyzed by Image-Pro Plus 6.0 software (Media Cybernetics, UK). 
 
2.2.16 Statistical Analysis 
Data are presented as mean ± SE of at least three independent experiments. Statistical 
significance of differences was assessed with the Student’s t-test. A value of P < 0.05 
was considered statistically significant. 
 
2.3 Results 
2.3.1 Bacterial Expression and Protein Purification 
High quality of recombinant His-S-CXCR2-C-tail (wild-type, PDZ motif deletion, PDZ 
motif mutation) and His-S-PLC-β3-C-tail proteins (wild-type, PDZ motif deletion, PDZ 
motif mutation) were produced as described in section 2.2.3. Figure 2-1 showed the 
purification of the bacterially expressed His-S-PLC-β3-C-tail (Fig. 2-1 A) and His-S- 
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CXCR2-C-tail (Fig. 2-2 B).  All the fractions were stained with Coomassie Brilliant Blue 
(Bio-Rad).  
 
2.3.2 Overexpression of CXCR2 in human pancreatic cancer cells 
The expression of CXCR2 in normal human pancreatic duct epithelial (HPDE) cells and 
several PDAC cell lines (HPAC, Colo357, PANC-1, and MIA PaCa-2) were examined 
and compared by Western blotting as described in section 2.2.6. All the five PDAC cell 
lines tested in our study showed significantly increased CXCR2 expression (both protein 
and mRNA) as compared to HPDE cells (Fig. 2-2), which is in agreement with the 
previous clinical study that reported an up-regulation of IL-8/CXCL8 and its receptors in 
both pancreatic adenocarcinomas and neuroendocrine tumors140. 
2.3.3 Endogenous CXCR2 and PLC-β3 in human pancreatic cancer cells 
preferentially interacts with NHERF1 
In a recent study, we demonstrated that the consensus PDZ motif at the carboxyl 
terminus of CXCR2 mediates PDZ-based interactions with certain PDZ scaffold proteins 
(such as NHERF1, NHERF2) in neutrophils163. In order to investigate if endogenous 
CXCR2 in PDAC cells binds to any PDZ scaffold proteins, we performed a pull-down 
assay 163 as described in Materials and Methods. As shown in Fig. 2-3 A, we observed 
interactions between CXCR2 and the membrane-associated PDZ proteins NHERF1 and 
NHERF2 in Colo357, L3.6pl, and HPAC cells, among which NHERF1 has a higher 
binding affinity for CXCR2 as compared with NHERF2. However, neither GST (the 
negative control) nor PDZK1 was found to bind to endogenous CXCR2 in these PDAC 
cell lines (Fig. 2-3 A). 
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CXCR2 couples to the pertussis toxin-sensitive Gi to stimulate phosphatidylinositide-
specific phospholipase C (PLC) activities145. Similar to CXCR2, all human PLC-β 
isoforms possess consensus class I PDZ motifs at their carboxyl termini162. Our 
previous study has demonstrated that PLC-β3, containing a PDZ motif (TQL-COOH), 
overexpressed in HEK293 cells interact with NHERF1 and NHERF2163. Here, we 
explored the potential interactions between PDZ scaffold proteins (NHERF1, NHERF2 
and PDZK1) and endogenous PLC-β3 in PDAC cell lines. By similar GST pull-down 
experiments, we observed that endogenous PLC-β3 in PDAC cells bind to both 
NHERF1 and NHERF2; however, it did not bind to PDZK1 or to GST alone (Fig. 2 -3 B). 
Moreover, in comparison to NHERF2, NHERF1 appears to interact with PLC-β3 with a 
higher affinity in most of the PDAC cell lines we tested (Fig. 2-3 B). In addition, the 
binding between endogenous PLC-β3 in PDAC cells and NHERF1 increased with 
increasing amounts of NHERF1 in a dose-dependent manner (Fig. 2-3 C). 
 
2.3.4 CXCR2 and PLC-β3 Interact with NHERF1 in a Direct and PDZ Motif-
Dependent Manner 
The data resulting from the GST pull-down studies presented above (Fig. 2-3) did not 
provide information whether the interactions between CXCR2 or PLC-β3 and NHERF1 
are direct, as cell lysates contain large numbers of other proteins as well. In order to test 
if CXCR2 or PLC-β3 binds NHERF1 directly or by other intermediary proteins, and to 
test the PDZ motif dependence, we performed a pair-wise binding assay that detects a 
direct interaction between purified proteins in vitro163. Purified His-S fusion proteins 
containing the C-tail fragments (last 45 amino acids) of CXCR2 WT, C-tail ∆TTL (with  
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PDZ motif TTL deleted), or C-tail AAA or ATA (with PDZ motif TTL mutated to AAA or 
ATA) were mixed with GST-NHERF1, and the mixtures were pulled down by S-protein-
agarose (the S-protein can specifically bind to the S-tag within the fusion proteins). The 
protein complex was immunoblotted with anti-NHERF1 antibody. We observed that the 
CXCR2 C-tail directly interacts with NHERF1 in a PDZ motif-dependent manner, as the 
interaction between NHERF1 and CXCR2 C-tail lacking the PDZ motif (∆TTL) or 
CXCR2 C-tail with PDZ motif mutations (AAA or ATA) was remarkably reduced (Fig. 2-
4A). We also observed that PLC-β3 C-tail (containing the PDZ motif) directly binds to 
NHERF1 in a PDZ motif-dependent manner, as the interaction between NHERF1 and 
PLC-β3 C-tail lacking the PDZ motif (∆TQL) or PLC-β3 C-tail with PDZ motif mutation 
(AAA) was almost completely abolished compared to wild-type (WT) PLC-β3 C-tail (Fig. 
2-4 B). 
 
2.3.5 CXCR2 interacts with both PDZ domains of NHERF1 (PDZ1 and PDZ2)  
We also showed that CXCR2 interacts with both PDZ domains of NHERF1 (PDZ1 and 
PDZ2) in the GST pull-down assays, with PDZ2 exhibiting higher binding affinities (Fig. 
2-5)128. Specifically, CXCR2 overexpressed in HEK293 cells were pulled down by using 
various purified GST-NHERF1 fractions (GST-PDZ1, GST-PDZ2, and GST-PDZ1-2). 
Whereas no CXCR2 was detected in the negative control lane containing GST alone, 
significant amounts of CXCR2 were found in the lanes containing PDZ1 domain (GST-
PDZ1), PDZ2 domain (GST-PDZ2), and both PDZ domains together (GST-PDZ1-PDZ2) 
(Fig. 2-5). To test whether the PDZ-CXCR2 interactions are direct, we performed an in 
vitro pair-wise binding assay with a biotinylated peptide containing the last 13 amino  
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 acids of CXCR2 (Biotin-FVGSSSGHTSTTL-COOH). Similar binding results were 
observed in the experiments where CXCR2 interacts with both PDZ domains of 
NHERF1 (Fig. 2-5). 
 
2.3.6 Endogenous PLC-β3 in human pancreatic cancer cells preferentially 
interacts with NHERF1-PDZ2  
We also demonstrated that endogenous PLC-β3 in various PDAC cells (PANC-1, MIA 
PaCa-2, AsPC-1, BxPC-3, and HPAC) preferentially interacts with PDZ2 domain of 
NHERF1. Specifically, the total cell lysates of PDAC cells (PANC-1, MIA PaCa-2, 
AsPC-1, BxPC-3, and HPAC) were mixed with various purified GST-NHERF1 fractions 
(GST-PDZ1, GST-PDZ2, and GST-PDZ1-2), and GST-NHERF1 full length. By the GST 
pull-down assays, we observed that the PLC-β3 endogenously expressed in all the 
PDAC cell lines preferentially interacts with PDZ2 domain with higher binding affinity 
(Fig. 2-6 A). It’s also worth mentioning that the binding affinity between PLC-β3 and 
PDZ2 domain is even stronger than the binding between PLC-β3 and full-length 
NHERF1. Morales and colleagues have demonstrated a head-to-tail intramolecular 
interaction between the PDZ2 domain and the C-terminal ezrin-radixin-moesin (ERM)-
binding region that could masks the association between NHERF1 and other PDZ 
domain ligands166,167. The higher binding affinity of PDZ2 domain compared to the full-
length NHERF1 protein is in agreement with the findings by Georgescu group. We also 
demonstrated the PLC-β3 interacts with both PDZ1 and PDZ2 domains of NHERF1 
directly by a pair-wise binding study (Fig. 2-6 B). Also, the PDZ2 domain has a slight 
higher binding affinity. 
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2.3.7 NHERF1 Clusters CXCR2 and PLC-β3 into a Macromolecular Complex both 
In Vitro and in human pancreatic cancer cells 
Results from the above GST pull-down experiments demonstrated that both 
endogenous CXCR2 and PLC-β3 in PDAC cells preferentially interact with NHERF1 
(Fig. 2-3 A and 2-3 B), and PLC-β3 binds to NHERF1 in a direct and PDZ motif-
dependent manner (Fig. 2-4 B), similar to the interaction between CXCR2 and NHERF1 
as we previously reported163. Hence, we hypothesized that NHERF1 might nucleate 
CXCR2 and PLC-β3 forming a macromolecular complex in a PDZ motif-dependent 
manner and this complex might be critical for efficient and specific signaling mediated 
by CXC-chemokine/CXCR2 biological axis in PDAC cells. Towards this end, we sought 
to determine if we could detect a macromolecular complex containing CXCR2, NHERF1, 
and PLC-β3 in vitro. Using an in vitro macromolecular complex assembly assay (Fig. 2-
7A)163, we observed the existence of a complex composed of CXCR2 C-tail, NHERF1 
and endogenous PLC-β3 in PDAC cells (Fig. 2-7 B). Furthermore, we demonstrated 
that CXCR2 C-tail did not bind to PLC-β3 directly, and the macromolecular complex was 
not formed by CXCR2 C-tail PDZ motif mutants (∆TTL or AAA), indicating that the 
formation of the CXCR2 macromolecular complex is PDZ motif-dependent (Fig. 2-7 B). 
In addition, we detected a similar complex consisting of PLC-β3 C-tail (containing the 
PDZ motif TQL), NHERF1, and endogenous CXCR2 from PDAC cells (data not shown). 
 
Results from the above demonstrated that a CXCR2 macromolecular complex exists in 
vitro; however, it did not provide the evidence whether this complex exists in native  
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 membranes of PDAC cells that endogenously express all the relevant interacting 
proteins. To address this issue, co-immunoprecipitation was performed using either 
anti-CXCR2 or anti-PLC-β3 antibodies as described in section 2.2.10. We observed that 
NHERF1 and PLC-β3 in PDAC cells were co-immunoprecipitated with CXCR2 (Fig. 2-7 
C). Similarly, CXCR2 and NHERF1 were also co-precipitated with PLC-β3 from PDAC 
cells (Fig. 2-7 D), indicating that there is likely to be a macromolecular complex 
composed of endogenous CXCR2, NHERF1 and PLC-β3 on the surface membranes of 
Colo357 and HPAC cells.  
2.3.8 CXC Chemokine/CXCR2 Biological Axis Promotes Pancreatic Cancer Cell 
Proliferation 
To examine the effect of CXCR2 signaling on PDAC cell proliferation, PDAC cells were 
treated with CXCR2 ligands followed by the MTT cell proliferation assay as described in 
section 2.2.11. As illustrated in Fig. 2-8 A, HPAC cells showed significantly elevated cell 
proliferative activities in response to both CXCL8 and CXCL1 (P < 0.05), and CXCL5 
also promoted HPAC proliferation, though without statistical significance (P = 0.07). 
Proliferation of Colo357 cells was significantly augmented by CXCL5 (P < 0.05), and 
also by CXCL8 and CXCL1 though without statistical significance (P = 0.09 and 0.2, 
respectively) (Fig. 2-8 B). It has been reported that Colo357 cells showed a significant 
high level of CXCL5 secretion73, and it has also been documented that CXCL5 is 
overexpressed in the pancreatic cancer patients compared to the normal individuals, 
which is associated with the poor survival in patients74. Our results underpinned the 
autocrine effects of CXCL5 on Colo357 cell proliferation. However, the normal 
pancreatic duct HPDE cells did not demonstrate significantly increased growth  
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 stimulated by the treatment of either of these CXCR2 ligands (CXCL1, CXCL5, or 
CXCL8) (Fig. 2-8 C), indicating that CXCR2 biological axis significantly promoted 
pancreatic cancer cell proliferation.  
 
2.3.9 Disrupting the CXCR2 Macromolecular Complex Inhibits Pancreatic Cancer 
Proliferation 
Given that the CXC-chemokine/CXCR2 biological axis plays an important role in PDAC 
cell proliferation (Fig. 2-8 A and 2-8 B), and here we also demonstrated that the PDZ 
motif of CXCR2 is essential for the physical coupling of CXCR2 to PLC-β3 mediated by 
NHERF1 into a macromolecular signaling complex (Fig. 2-7 B); therefore, it is possible 
that perturbation of the CXCR2 macromolecular complex might affect CXCR2 ligand-
induced PDAC cell proliferation. In a recent study, we utilized a CXCR2 C-tail peptide 
(containing the PDZ motif) to disrupt the CXCR2 PDZ motif-mediated interaction with 
NHERF1 and observed a functional inhibition of CXCR2 ligand-induced cell migration in 
neutrophils163. We went on to evaluate the functional significance of this CXCR2 
macromolecular complex in the CXCR2 ligand-induced PDAC cell proliferation. We 
transfected HPAC and Colo357 cells with plasmids encoding CXCR2 C-tail (WT or PDZ 
deletion ∆TTL), and evaluated cell proliferative activities. As shown in Fig. 2-9 A, in 
response to CXCL5, Colo357 transfected with plasmid containing CXCR2 C-tail WT 
showed significantly reduced proliferative activities as compared to cells transfected 
with the vector alone or CXCR2 C-tail ∆TTL, suggesting that disrupting CXCR2 
macromolecular complex inhibits CXCR2 ligand-induced Colo357 growth, and PDZ 
motif on the C-terminus of CXCR2 is important for PDAC cell proliferation. HPAC  
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 transfected with CXCR2 C-tail WT showed significantly decreased cell proliferation in 
response to CXCL8 (Fig. 2-9 B). In addition, we delivered the CXCR2 C-tail peptides 
(WT and ∆TTL) used in our previous studies163 to Colo357 and HPAC cells, and we 
also observed significantly reduced cell proliferation stimulated by CXCL5 (Fig. 2-9 C) 
and CXCL8 (Fig. 2-9 D). Furthermore, using the pair-wise binding assay, we also 
demonstrated that the CXCR2 C-tail peptide interacts with NHERF1 in a direct and PDZ 
motif-dependent manner, because the CXCR2 WT peptide interacts with NHERF1, 
while the PDZ deletion peptide (∆TTL) or mutation peptide (AAA) failed to bind to 
NHERF1 (Fig. 2-9 E). 
 
2.3.10 Inhibitory effect of EF1060 on MIA PaCa-2 proliferation 
The peptide inhibitor, EF1060, was dissolved in DMSO as 200mM stock with good 
solubility. Initially, concentration (500 ng/ml) of EF1060 was used to compare with the 
peptide synthesized by Genemed Synthesis (Biotin-CXCR2 C-tail; 13 a.a.). Significant 
change in cell proliferation was not detected at the peptide concentration of 500ng/ml 
(of 96-well plate) (Fig. 2-10 B). 
 
However, by using similar peptide concentration (200µg/ml) that was previously 
reported by Dr. Spaller’s group, significant reduction in cell proliferation by EF1060 has 
been observed compared with DMSO control (Fig. 2-10 C). 
It is noteworthy that, EF1060, when used at low concentration (in Fig. 2-10 B) without 
Chariot, seemed to have inhibitory effect on cell proliferation, although had not achieved 
statistical significance given the small sample number. Meanwhile, EF1060 significantly  
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 inhibited cell proliferation when used at high concentration without Chariot (as in Fig.2-
10 C). However, when used at low concentration (in Fig. 2-10 B), EF1060 (+ ChariotTM) 
had no effect on cell proliferation, which suggests that EF1060 with myristoylation at N-
terminus might not require the commercial peptide delivery system. 
 
2.3.11 Disrupting the CXCR2 Macromolecular Complex Blocks Pancreatic Cancer 
Cell Invasion 
We then examined the effect of disrupting CXCR2 signaling complex on the invasive 
capability of PDAC cells. HPAC cells were transfected with plasmids encoding CXCR2 
C-tail (WT or ∆TTL) and used to evaluate the invasive potency by an in vitro invasion 
assay as reported before73. As illustrated in Fig. 2-11, gene delivery of CXCR2 C-tail 
WT sequence, but not the ∆TTL PDZ deletion sequence, significantly inhibited invasion 
of HPAC cells through Matrigel induced by CXCL8, implicating that the PDZ motif of 
CXCR2 is important for PDAC cell invasion.  
 
2.3.12 Disrupting the CXCR2 Macromolecular Complex Blocks Pancreatic Cancer-
induced angiogenesis 
We next investigated the effect of disrupting CXCR2 macromolecular complex on the 
capability of PDAC cell-induced angiogenesis. PANC-1 cells were transfected with 
plasmids encoding CXCR2 C-tail (WT or ∆TTL) and used to evaluate the tumor-induced 
angiogenesis potential by an in vitro tube formation assay as described in section 2.2.13. 
Figure 2-12 showed that gene delivery of CXCR2 C-tail WT sequence, but not the ∆TTL  
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 PDZ deletion sequence or pTriEx4 vector alone, significantly suppressed the tube 
formation of HUVEC cells induced by the PANC-1 cells, indicating the CXCR2 
macromolecular complex through PDZ binding is important for PDAC-induced 
angiogenesis. 
 
2.3.13 Disrupting the CXCR2 Macromolecular Complex Inhibits Pancreatic Tumor 
Growth In Vivo 
To analyze the functional significance of the CXCR2 macromolecular complex in PDAC 
growth in vivo, a subcutaneous xenograft induced by HPAC cells in CB17-SCID mice 
was developed to determine whether disrupting the CXCR2 signaling complex could 
lead to inhibition of tumor growth in vivo. HPAC cells that were transduced with Adeno-
Associated Virus (Serotype 2) expressing GFP - human CXCR2 C-tails (WT or ∆TTL) or 
GFP alone, or non-transduced cells, were injected subcutaneously into CB17-SCID 
mice. The transduction efficiency was inspected visually under the fluorescence 
microscope (Fig. 2-13). Tumor volume was measured every other day starting at day 12 
(when the tumor became palpable). At day 28, all mice were euthanized, and tumors 
were excised and final tumor weights were determined by the scale. We found that 
HPAC cells expressing GFP alone or GFP-CXCR2 C-tail ∆TTL grew into sizable tumors 
underneath the skin that were comparable to non-transduced cells (Fig 2-14 A). 
However, HPAC cells expressing GFP-CXCR2 C-tail WT grew into significantly smaller 
tumors compared with the cancer cells expressing GFP vector alone or GFP-CXCR2 C-
tail ∆TTL, or non-transduced cells (Fig 2-14 A). Furthermore, the HPAC cells, 
transduced with GFP-CXCR2 C-tail WT, showed significantly reduced final tumor weight  
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compared to the 3 other groups (Fig. 2-14 B). This result suggests an inhibitory effect of 
exogenous CXCR2 C-tail (containing the PDZ motif) on human pancreatic tumor 
development and progression in vivo. We then demonstrated that the proliferation index, 
determined by Ki-67 expression, in the group of mice injected with HPAC cells 
expressing GFP–CXCR2 C-tail WT was significantly lower (p < 0.01) compared to the 3 
other groups (non-transduction group, AAV2-GFP group, and AAV2-GFP-CXCR2 C-tail 
∆TTL group) (Fig. 2-14 C and D). Collectively, our date indicates the potential 
therapeutic effect of disrupting the CXCR2 macromolecular complex on the primary 
tumor of PDAC in a subcutaneous mouse model. It is noteworthy that in the group of 
mice injected with HPAC cells expressing GFP–CXCR2 C-tail WT did not show 
significant reduced in vivo tumor-induced angiogenesis compared to other groups.  
 
2.4 Discussion 
CXC-chemokines (such as CXCL1/GRO-α, CXCL8/IL-8, CXCL5/ENA-78) and their 
cognate receptor CXCR2 have been reported to play a critical role in tumor growth and 
tumor invasion and tumor-induced angiogenesis, as blockade of the CXC-
chemokines/CXCR2 biological axis reduced tumorigenesis and angiogenesis in many 
human cancers including pancreatic cancer63,73,75,168. However, most of the 
interventional approaches have been conducted by systemic blockade or depletion of 
CXCR2 and/or its ligands, which might cause global undesired effects on other vital 
functions, as CXCR2 had also been reported in many essential normal cellular functions, 
such as in preservation of oligodendrocyte function and myelinization of neural tissues21. 
This issue warrants the necessity of a more comprehensive understanding of the  
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 molecular mechanisms of CXCR2 and its signaling, on the basis of which, selective 
and cell-specific therapeutic targets could be identified.  
 
CXCR2 possesses a consensus PDZ motif at their carboxyl termini, and the PDZ motif 
has been reported to modulate cellular chemotaxis123. Recently, we demonstrated that 
the PDZ motif of CXCR2 plays an important role in regulating neutrophil functions as 
disrupting the interaction mediated by PDZ motif via using an exogenous peptide mimic 
(mapping CXCR2 PDZ motif) significantly inhibited CXCR2-mediated calcium 
mobilization and neutrophilic transepithelial migration163. In the present study, we 
identified the PDZ scaffold protein NHERF1 as a previously unrecognized interacting 
partner for CXCR2 in PDAC cells, and we also demonstrated the existence of a PDZ-
based CXCR2 macromolecular signaling complex containing endogenous CXCR2, 
NHERF1 and PLC-β3 in PDAC cells. Furthermore, we provided functional evidence 
showing that disrupting the CXCR2 complex significantly inhibited the malignant cellular 
functions (i.e. proliferation and invasion) in vitro and pancreatic tumor growth in vivo. 
 
Controversy exists regarding the expression of CXCR2 in human pancreatic cancer cell 
lines. Despite some studies reported that CXCR2 was not detected in some human 
PDAC cell lines (such as PANC-1, MIA PaCa-2, AsPC-1, BxPC-3 and HPAF-II)73,165,169, 
other groups reported the detection of CXCR2 and/or the autocrine effect of CXCR2 
ligands in various human PDAC cells74,141-144,170 (such as PANC-1, MIA PaCa-2, Capan-
1, Capan-2, SUIT-2, HuP-T4, Bx-PC-3, Panc03.27), and pancreatic tumors specimens 
from patients63,140. In the present study, we also detected the expression of CXCR2 in 
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PANC-1, MIA PaCa-2, HPAC, Colo357, and L3.6pl cells in Western blotting (Fig. 2-2 A) 
by using the same antibody Frick et al used to detect the CXCR2 expression in patient 
specimens63. RT-PCR results from our study also confirmed the expression of CXCR2 
in these cell lines (Fig. 2-2 B). One possible reason for the failure of some groups to 
detect CXCR2 in PDAC cell lines might be that expression level of CXCR2 varies in 
different conditions. Yamamoto et al reported that CXCR2 is up-regulated in an 
orthotopic colon cancer model compared to the subcutaneous model171. Hussain et al 
also reported that the expression level of CXCR2 correlates with tumor grade and stage 
in pancreatic adenocarcinomas140.   
 
PLC-β is the major isozyme that has been well-studied to participate in GPCR-mediated 
signaling and modulate the physiological responses, such as promoting cell growth in 
many cancer types172-174. Each PLC-β subtype has its distinct expression pattern and 
physiological relevance172. Among the four subtypes of PLC-β, PLC-β3 is expressed in 
a wide range of cells and tissues174, and exhibits the highest affinity to Gβγ subunits and 
subsequent activation by Gβγ subunits175. A growing body of evidence suggests that 
PDZ scaffold proteins are involved in the modulation of PLC-β isoforms in the PDZ 
motif-dependent manner. PLC-β3, with its PDZ motif (-STQL-COOH), was reported to 
bind to PDZ domains of NHERF2 and Shank2 via its PDZ motif at its carboxyl termini, in 
mouse small intestine161 and in the postsynaptic density region in neuronal cells158, 
respectively. It has also been shown that PLC-β3 was down-regulated in jejuna villus 
cells in NHERF1- knockout mice160. Results from our present study revealed that PLC-
β3 preferentially binds to NHERF1 in PDAC cells in a direct and PDZ motif-dependent 
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pattern. Therefore, the specificity and diversity of agonist-induced PLC-β activity and its 
downstream signaling may be regulated by the specific interactions of PLC-β isoforms 
and certain PDZ scaffold proteins.  
 
There is accumulating evidence suggesting that the formation of spatial compact 
macromolecular signaling complexes beneath the plasma membrane enables the 
membrane receptors to transduce signals into cell interior and thereafter influence cell 
behavior with higher specificity and efficiency163,176-179. These findings have therapeutic 
implications in various diseases including inflammatory diseases, genetic diseases and 
cancer153-159. Our present study revealed a PDZ motif-dependent CXCR2 
macromolecular signaling complex, in which CXCR2 and PLC-β3 were bridged by 
NHERF1, in the PDAC cells (Fig. 2-15). Results from our study also demonstrated the 
functional importance of the CXCR2 complex in pancreatic cancer cell functions in vitro 
and in vivo, as disturbing the CXCR2 complex by using an exogenous CXCR2 C-tail 
sequence (containing the PDZ motif) significantly attenuated malignant cell proliferation 
and cell invasion of PDAC cells and tumor growth in vivo. Our present study introduced 
a new concept of the CXCR2 macromolecular complex mediated via PDZ-based 
interactions, and we elucidated the molecular evidence and functional importance of this 
CXCR2 complex in pancreatic cancer progression. Moreover, by investigating a network 
of protein complexes rather than CXCR2 alone in pancreatic cancer, our results reveal 
a novel molecular target for the development of specific therapeutic strategies and 
agents that could combat pancreatic cancer.  
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Recent advances regarding PDZ proteins have suggested that the specific inhibition of 
the protein-protein interaction mediated by PDZ domains, with subsequent intervention 
of the signaling pathways mediated by the PDZ proteins, appears to be a promising 
strategy for developing novel peptide inhibitors in cancer180. Furthermore, our studies 
have shown that our CXCR2 specific peptide (bearing the last 13 residues of the C-
terminal sequence of CXCR2) exhibit significant inhibitory effect on the malignant 
cellular functions of pancreatic cancer125. However, before the clinical trials commence, 
our strategy still needs to be further investigated by addressing several challenges. The 
membrane permeability of the small peptide is one of the frequently questioned 
problems in novel inhibitor development180. Also, additional effort is also required on 
maximizing the binding affinity and specificity of the peptide inhibitors. Recent studies 
have reported that myristate, a saturated 14-carbon alkyl acid, would function as a 
promising delivery system for membrane transport181-183. Furthermore, it has been 
suggested that organic halogen modifications appear to be promising strategies to 
enhance the binding affinity and specificity of the novel peptide inhibitors, as the 
halogen atoms have been reported to enhance the stability of protein-ligand 
interaction184,185, increase the binding contacts186, and also improve the membrane 
permeability186. Dr. Mark Spaller’s group from Dartmouth College recently reported a 
novel peptide targeting the PDZ domain of GAIP-interacting protein, C terminus (GIPC) 
bearing the last 8 residues of the C-terminal sequence of GAIP (N-myristoyl-
PSQSKSKA). The peptide was modified by chemical substitution of two bromobenzoate 
moieties at the “-1” and “-3” positions180. The halogenated benzoyl-group has introduced 
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the new potential contacts between the “-1” and “-3” residues and the PDZ domain, 
resulting in the significantly increased inhibitory effect of this peptide compared to the 
non-modified peptide. Similar enhanced inhibitory effects of the halogenated 
modification have been observed in other peptide, such as flavopiridol187. Further 
studies should involve control peptides to test the specificity of the peptide inhibitor 
(peptide with scrambled sequences, or CXCR2 PDZ mutation peptide such as Myr-
SGHTSAAA or Myr-SGHTS). 
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Chapter III 
Crystallographic Analysis of NHERF1-PLCβ3 Interaction Provides Structural 
Basis for CXCR2 Signaling in Pancreatic Cancer 
© 2014 Elsevier 
 
3.1 Introduction: 
CXC chemokine receptor 2 (CXCR2) was initially identified as the neutrophil receptor 
that is activated by binding to interleukin-8188. Besides the roles in mediating 
neutrophilic migration and positioning of oligodentrocyte precursors in developing spinal 
cord 163,189,190, a growing body of evidence has suggested that the enhanced expression 
of CXCR2 correlates with aggressive stages and poor survival in pancreatic cancer 
patients 62,191. More recent studies have also revealed that CXCR2 and its ligands 
(CXCL1, CXCL5, and CXCL8) are overexpressed in pancreatic ductal adenocarcinoma 
cell lines and enhance cell proliferation141,144,192. The evidence has made CXCR2 an 
attractive drug target for developing highly-specific inhibitors for pancreatic cancer. 
 
Recent studies regarding protein-protein interactions suggested that CXCR2 interacts 
with other proteins, including ion channels, transporters, scaffolding proteins, and 
cytoskeletal elements to form macromolecular complexes at specific subcellular 
domains within cytoplasma163,192. These dynamic protein-protein interactions regulate 
CXCR2 signaling function as well as its localization and processing within cells 193,194. In 
chapter 2, I have detected a macromolecular complex containing CXCR2, Na+/H+ 
exchanger regulatory factor-1 (NHERF1), and phosphoipase C-β3 (PLC-β3), at the 
plasma membrane of pancreatic cancer cells, which functionally initiated the CXCR2 
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signaling cascade through PLC-β3192. PLC-β3, a membrane bound enzyme, catalyzes 
the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 
4,5-bisphosphate. NHERF1 is a PDZ domain-containing protein that typically functions 
as a scaffold to cluster transporters, receptors, and signaling molecules into 
macromolecular complexes 195. In chapter 2, I have already demonstrated that the 
formation of the CXCR2 macromolecular complex is mediated by PDZ-binding through 
the PDZ domains in NHERF1 and the PDZ binding motifs from CXCR2 (-STTL-COOH) 
and PLC-β3 (-STQL-COOH). I also showed that disruption of this PDZ-mediated 
interaction attenuated the cellular functions (i.e. proliferation, invasion, and tumor 
growth) in pancreatic cancer, implicating that targeting the PDZ binding-mediated 
CXCR2-PLC-β3 interaction could provide new strategies for therapeutic interventions. 
 
In general, PDZ domains recognize the C-terminal sequences of the target proteins (i.e. 
membrane receptors, ion channels, etc.) and bind to the targets via a canonically and 
structurally conserved PDZ peptide-binding pocket196, thereby mediating the protein-
protein interactions and the formation of macromolecular complex. The specificity of the 
interactions is primarily determined by the amino acids at positions 0 and -2 of the C-
terminal sequences of the target proteins, whereas other residues do not significantly 
contribute to the interaction (position 0 refers to as the extreme residue at the C-
terminus) 196. The characteristics of the side chains of the residues at 0 and -2 positions 
have led to the classification of the PDZ domains into two major classes: I, S/T)X(V/I/L) 
(X denoting any amino acid); class II, (F/Y)X(F/V/A) 197-199. However, more recent 
studies have suggested that the specificity of the PDZ binding is unexpectedly 
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complicated, with the PDZ domain family recognizing up to 7 C-terminal residues and 
forming multiple PDZ binding classes200. The promiscuity of the binding between 
different PDZ binding motifs and distinct PDZ domains raises a challenging problem of 
how PDZ domains, which are structurally simple protein interaction modules, achieve 
the broad substrate specificity. In this chapter, crystal structure of the complex, 
NHERF1-PDZ1 with the PLC-β3 C-terminal peptide ENTQL, reveals that the PLC-β3 
peptide binds to PDZ1 domain in an extended conformation with the last four residues 
making specific side chain contacts. The results that PLC-β3 can bind both NHERF1 
PDZ1 and PDZ2 in PDAC cells (chapter 2), are consistent with the observation that the 
two PDZ domains, PDZ1 and PDZ2, share the peptide-binding pockets which are highly 
structurally conserved. The study in this chapter provides the structural basis of the PDZ 
interaction-mediated NHERF1-PLCβ3 interaction, and provides the novel insights in 
development of novel therapeutic strategies against lethal pancreatic cancer. 
 
3.2 Materials and Methods 
3.2.1 Protein Expression and Purification 
For X-ray crystallography, a DNA fragment encoding the human NHERF1 PDZ1 
(residues 11–94) was amplified by PCR using the full-length human NHERF1 cDNA as 
a template. The C-terminal extension ENTQL that corresponds to residues 1230–1234 
of human PLCβ3 was created by inclusion of 15 extra bases in the reverse primer. The 
PCR products were cloned in the pSUMO vector containing an N-terminal His6-SUMO 
tag. The resulting clone was transformed into Escherichia coli BL21 Condon Plus (DE3) 
cells for protein expression. The transformants were grown to an OD600 (optical density 
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at 600 nm) of 0.4 at 37 °C in LB medium, and then i nduced with 0.1 mM isopropylthio-β-
D-galactoside at 15 °C overnight. The cells were ha rvested by centrifugation and lysed 
by French Press. The soluble fraction was then subjected to Ni2+ affinity 
chromatography purification, followed by the cleavage of the His6-SUMO tag with yeast 
SUMO Protease 1. PDZ1 proteins were separated from the cleaved tag by a second 
Ni2+ affinity chromatography and further purified by size-exclusion chromatography. 
Finally, the proteins were concentrated to 30–40 mg/ml in a buffer containing 20 mM 
Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM β-mercaptoethanol, and 5% glycerol. For 
pulldown experiments, glutathione S-transferase (GST) fusion proteins were generated 
by cloning NHERF1 PDZ1, PDZ2, or PDZ1-PDZ2 into the pGEX4T-1 vector 163. His-S-
tagged proteins were generated by cloning PLCβ3 C-terminal fragment (residues 1135–
1234) into the pET30 vector 192. GST-PDZ proteins were purified using glutathione 
agarose beads (BD Biosciences) and eluted with 50 mM glutathione. His-S-PLCβ3 was 
purified using Cobalt resins (Thermo Scientific) and eluted with 200 mM imidazole. 
3.2.2 Crystallization, Data Collection and Structure Determination 
Crystals were grown by the hanging-drop vapor-diffusion method by mixing the protein 
(~25 mg/ml) with an equal volume of a reservoir solution containing 100 mM sodium 
acetate, pH 4.6, 2.5 M sodium chloride at 20 °C. Cr ystals typically appeared overnight 
and continued to grow to their full size in 3–4 days. Prior to X-ray diffraction data 
collection, crystals were cryoprotected in a solution containing the mother liquor and 
25% glycerol and flash cooled in liquid nitrogen. The data were collected at 100 K at 
beamline 21-ID-F at the Advanced Photon Source (Argonne, IL) and processed and 
scaled using the program XDS 201. Crystals belong to the space group P3121 with unit  
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Table 3-1. Crystallographic data and refinement statistics 
Data 
 
Space group P21 
Cell parameters (Å)  
a 26.4 
b 40.3 
c 37.1 
Wavelength (Å) 1.2719 
Resolution (Å) 24.2-1.34 (1.37-
Rmergea 0.039 (0.250)b 
Redundancy 4.1 (4.0) 
Unique reflections 17966 
Completeness (%) 99.8 (99.6) 
〈I/σ〉 15.3 (3.0) 
Refinement 
 
Resolution (Å) 24.2-1.34 (1.37-
Molecules/AU 1 
Rworkc 0.145 (0.268) 
Rfreed 0.177 (0.275) 
Ramachandran plot  
Residues in favored 97.9% 
Residues in allowed 2.1% 
RMSD  
Bond lengths (Å) 0.007 
Bond angels (°) 1.2 
No. of atoms  
Protein 1347 
Peptide 73 
Water 143 
Chloride 2 
B-factor (Å2)   
Protein 17.2 
Peptide 17.7 
Water 28.5 
Chloride 20.2 
SCN 12.4 
aRmerge= Σ|I-〈I〉| / ΣI, where I is the observed 
intensity and 〈I〉 is the averaged intensity of 
multiple observations of symmetry-related 
reflections. 
bNumbers in parentheses refer to the 
highest resolution shell. 
cRwork= Σ|Fo-Fc| / Σ|Fo|, where Fo is the 
observed structure factor, Fc is the 
calculated structure factor. 
dRfree was calculated using a subset (5%) of 
the reflection not used in the refinement. 
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cell dimensions a = b = 50.7 Å, c = 66.7 Å, and one molecule in the asymmetric unit 
(Table 1). The structure was solved by the molecular replacement method with the 
program PHASER 202 using the PDZ1-CXCR2 structure (PDB code: 4JL7) as a search 
model. Structure modeling was carried out in COOT203, and refinement was performed 
with PHENIX 204. To reduce the effects of model bias, iterative-build OMIT maps were 
used during model building and structure refinement. The final models were analyzed 
and validated with Molprobity205. All figures of 3D representations of the PDZ1-PLCβ3 
structure were made with PyMOL (www.pymol.org). 
 
3.2.3 Protein Data Bank Accession Number 
Coordinates and structure factors have been deposited in the Protein Data Bank with 
accession number 4PQW. 
 
3.3 Results 
Binding specificity of NHERF1-PLC-β3 Interaction 
The overall structure of NHERF1-PDZ1 is similar to other PDZ domains199,206, consisting 
of six β strands (β1–β6) and two α-helices (αA and αB) (Fig. 3-1 A and Fig. 3-1 B). The 
PLC-β3 peptide binds in the cleft between β2 strand and αB helix, burying a total 
solvent-accessible surface area of 600 Å2. The binding specificity of the PDZ1-PLC-β3 
interaction is achieved through networks of hydrogen bonds and hydrophobic 
interactions (Fig. 3-1 C). At the ligand position 0, the side chain of Leu0 is nestled in a 
deep hydrophobic pocket formed by invariant residues Tyr24, Phe26, and Leu28 from 
β2 and Val76 and Ile79 from αB (Fig. 3-1 D). In the binding pocket, the position of Leu0  
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 is further secured by both a hydrogen bond from its amide nitrogen to the Phe26 
carbonyl oxygen and triplet hydrogen bonding between the Leu0 carboxylate and the 
amides of Tyr24, Gly25, and Phe26. Similar interactions have been observed in several 
other PDZ-mediated complexes199,206, which represent the most-conserved binding 
mode for terminal Leu recognition. 
 
Residues at other positions also contribute to the PDZ1-PLC-β3 complex formation (Fig. 
3-1 C). At the position -1, the aliphatic portion of the Gln-1 side chain makes Van der 
Waals interaction with the imidazole ring of His27. At position -2, Thr-2 makes one 
hydrogen bond to the His72 imidazole group and two hydrogen bonds to the highly 
conserved residue Leu28. At the position -3, the interactions with Asn-3 include a direct 
hydrogen bond from its side chain oxygen to the Nη1 atom of Arg40 and a water-
mediated hydrogen bond to the Nε atom of Arg40. The latter two interactions represent 
ligand specific interactions, as the small side chain of Ser-3 is recognized by His29 in 
PDZ1-CXCR2 complex129,207. Finally, the peptide residue Glu-4 engages in a main 
chain contact with Gly30, but does not participate in any specific side chain interactions. 
These observations indicate that the last four residues of PLC-β3 contribute to the 
binding specificity in the PDZ1-PLC-β3 complex formation. 
 
To understand the structural basis of the bivalent binding, we performed a structural 
alignment between the structure of NHERF1 PDZ1 and the structure of NHERF1 PDZ2. 
The alignment reveals that NHERF1 PDZ1 and PDZ2 share highly similar overall 
structures and highly conserved ligand-binding pockets (Fig. 3-2). The root mean  
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 square (rms) difference is 0.63 Å for the overall structure (92 Cα atoms), and for the 
ligand-interacting residues, 0.27 Å. The only distinct difference in the ligand-binding 
sites is residue 27, which is His in PDZ1 and Asn (residue 164) in PDZ2. It is 
noteworthy that this conserved substitution maintains the amino functionality of the side 
chain, which is not expected to disrupt the observed Van der Waals contact between 
PDZ1 and PLC-β3 (Fig. 3-1 C). Therefore, the comparison of PDZ1 and PDZ2 provides 
a structural explanation for the ability of PLC-β3 to bind to both PDZ domains. 
 
3.4 Discussion 
Our previous study has suggested that targeting the PDZ-mediated CXCR2 
macromolecular complex have a therapeutic potential in PDAC treatment, as disruption 
of this interaction has been found to inhibit cellular functions both in vitro and tumor 
growth in vivo192. These findings highlight the significance of our present structure 
studies and also indicate that the structural details of the NHERF1-PLC-β3 interaction 
could open the new avenues in developing novel methods and strategies for selective 
drug design (i.e. design new NHERF1 inhibitors that could block the NHERF1-PLC-β3 
interaction with high specificity). Such inhibitors have the potential to inhibit pancreatic 
tumor growth by suppressing CXCR2 signaling and preventing tumor cell proliferation 
and invasion. In addition, the fact that PLC-β3 binds to both PDZ domains of NHERF1 
(Fig. 2-6), together with structural similarity of PDZ1 domain and PDZ2 domain (Fig. 3-
2), suggests NHERF1 inhibitors may be capable of targeting PDZ1 and PDZ2 
simultaneously. Such inhibitors might be advantageous in cancer treatment, as PDZ1 
and PDZ2 have been shown to have differential roles during metastasis. NHERF1 
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PDZ2 promotes visceral metastasis via invadopodia-dependent invasion and 
anchorage-independent growth, as well as by inhibition of apoptosis, while PDZ1 
promotes bone metastasis by stimulating podosome nucleation, motility, angiogenesis, 
and osteoclastogenesis in the absence of increased growth or invasion208. It is 
conceivable that simultaneous targeting of the PDZ domains could lead to a 
combinatorially synergetic effect that would prevent cellular functions in pancreatic 
cancer. The biological impact of the bivalent NHERF1-PLC-β3 interaction remains 
mysterious, which directs future studies toward the evaluation of its effect on CXCR2-
mediated cellular functions in pancreatic cancer. Especially, it is worthy determining 
whether different PDZ domains could mediate the assembly of distinct CXCR2 signal 
transduction complexes. 
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Chapter IV 
Conclusion and Future Directions 
 
4.1 Conclusion 
Pancreatic cancer is a disease with poor prognosis, high level of mortality, significant 
high death rates, and accounting for 6 ~ 7% of all cancer-related deaths for both men 
and women in the United States. Thus, a more comprehensive understanding of the 
biology of PDAC and the mechanisms/factors that promote invasion and tumor growth 
may help identify new molecular targets for the development of diagnostics and/or 
therapeutics of pancreatic cancer. 
 
My dissertation research study has identified a CXCR2 macromolecular complex 
(CXCR2•NHERF1•PLC-β3) in human pancreatic cancer cells, the scaffolding protein 
NHERF1 clusters CXCR2 and PLC-β3 in close proximity via a specific PDZ domain-
based interaction, thereby forming spatially compact signaling complexes beneath the 
plasma membrane. Consequently, the CXCR2 macromolecular complex enables 
CXCR2 to transduce its signal to PLC-β3 with efficiency and specificity. Using various 
cellular functional assays and an in vivo model, we also demonstrated this CXCR2 
macromolecular complex is critical for the malignant cellular functions of pancreatic 
cancer including cell proliferation, cell invasion, tumor-induced angiogenesis, and tumor 
growth in vitro and in vivo. We further tested a peptide inhibitor specifically designed 
based on CXCR2 PDZ-mediated protein-protein interaction, and showed that this 
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peptide inhibitor significantly inhibited the malignant cellular functions of pancreatic 
cancer cells, suggesting that it could be a promising strategy for further drug design. 
 
Our findings of the functional significance and therapeutic potential of the interaction 
between CXCR2 and NHERF1 in pancreatic cancer may be valuable in the 
development of innovative strategies for targeted drug discovery. Systemic blockade of 
CXCR2 is the primary approach being used currently. However, the important roles of 
CXCR2 in regulation of normal physiology (including early tumor surveillance and 
immune system physiology) warrants the necessity to identify novel CXCR2 inhibitors, 
which can be more tissue-specific and/or disease-specific112. The results of this 
dissertation project have proved that the PDZ-mediated interaction between CXCR2 
and NHERF1 is important in pancreatic cancer, and targeting this interaction could 
represent novel approach to tackle this lethal disease. Also, our subsequent structural 
analysis have revealed the structural specificity between NHERF1 and CXCR2/PLC-β3, 
and provided insights that would be valuable for designing CXCR2 inhibitors that are 
specific to the CXCR2-NHERF1 interaction without cross-inhibiting any of the other 
NHERF1-coordinated signaling events, considering the complexity of the NHERF1 
interaction network and its versatile roles in regulation of many cellular processes 
essential to normal physiology130,131.  
 
4.2 Future Directions 
4.2.1 Investigation of the effect of the CXCR2 macromolecular complex in CXCR2 
signaling 
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CXCR2 couples to the pertussis toxin-sensitive Gi proteins to stimulate 
phosphatidylinositide-specific phospholipase C (PLC) activities209. PLC molecules can 
be divided into six families of isozymes: β, γ, δ, ε, η, and ζ210. The β family consists of 
four isoforms, PLC-β1 to PLC-β4. PLC-β2 has been detected primarily in hematopoietic 
cells, whereas PLC-β1 and PLC-β3 are found in a wide range of cells and tissue174. 
PLC-β4 is predominantly expressed in certain neuronal cells211,212. Activation of PLC-β 
results in hydrolysis of the lipid phosphatidylinositol 4, 5-bisphosphate, generating 
diacylglycerol (DAG), which activates PKC isoforms, and inositol 1,3,4-triphosphate 
(IP3), which releases calcium from intracellular stores. Stimulation of PDAC cells with 
CXCR2 ligands (such as CXCL1, CXCL5, and CXCL8) results in increases in cytosolic 
calcium due to a combination of intracellular calcium release mediated by inositol 1,3,4-
triphosphate (IP3) and an influx of extracellular calcium. Furthermore, we have already 
demonstrated that PLC-β3 and CXCR2 is nucleated by NHERF1 into a macromolecular 
complex (see section 2.3.7). The specific interactions of different PLC-β3 with NHERF1 
may be responsible for the specific intracellular cell signaling (e.g. intracellular calcium 
mobilization) induced by CXCR2 biological axis. Our previous study also demonstrated 
that CXCR2 peptide (WT) disrupted the CXCR2 macromolecular complex and inhibited 
intracellular Ca2+ increase in neutrophils124. Therefore, this peptide may also have 
similar inhibitory effect on the CXCR2 ligands elicited calcium signals in pancreatic 
cancer cells. In order to test the effect of the CXCR2 peptide (WT) on CXCL5/8 induced 
intracellular calcium mobilization, I will deliver this peptide into pancreatic cancer cells, 
and then measure the intracellular calcium moblization induced by CXCL5/8 as 
described above124. My prediction is that the CXCR2 peptide (WT), when delivered into 
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PDAC cells, will disrupt the macromolecular complex (CXCR2•NHERF1•PLC-β3) by 
competing with the endogenous CXCR2 for binding to NHERF1; and PDAC cells 
delivered with this peptide will show markedly reduced calcium signals compared to the 
control. The CXCR2 peptide (∆TTL) will be used in parallel to demonstrate whether the 
PDZ motif of CXCR2 is critical for the CXCL5/8-induced calcium mobilization. 
 
Also, to confirm the specificity of the CXCR2 peptide in the CXCL5/8-induced calcium 
signal, other peptides (e.g. C-terminal peptides of CFTR, or LPAR2 receptor 
synthesized by Genemed Synthesis. Please note: all of these peptides contain the PDZ 
motif consensus at their C-termini154) will also be delivered into PDAC cells in parallel as 
controls, followed by measurement of the intracellular calcium mobilization induced by 
CXCL5/8. In addition, the effect of CXCR2 peptide will also be assessed in the other 
ligands-induced calcium mobilization in PDAC cells, such as bradykinin (BK), 
cholecystokinin (CCK)165. My prediction is that the CXCR2 peptide (both WT and ∆TTL) 
will not affect the intracellular calcium signals induced by BK or CCK, but will only inhibit 
the CXCL5/8 induced calcium signals. 
 
4.2.2 Further Characterization of Interactions between NHERF1 and CXCR2 by 
Flourescence Recovery After Photobleaching (FRAP) 
 
Flourescence Recovery After Photobleaching (FRAP) is an optical technique for 
measuring membrane transport or two dimensional lateral diffusion of fluorescent 
molecules on the cell membrane213-215. The FRAP technique was initially developed 
back in the 70’s, and was primarily used to investigate the lateral diffusion of the 
membrane proteins in single cells216-218. Recently, with the rapid development of the 
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fluorescent-fused protein technology, FRAP technique has been increasingly used in 
investigating the protein-protein interactions and macromolecular dynamics in the living 
cells. Qualitative assessment of the recovery rate (slower or faster) has been used to 
characterize specific perturbations of the protein-protein interaction219.  
 
Briefly, all the fluorescent probes or fluorescent-fused proteins could emit light of one 
wave length (e.g. green) after the light of another wavelength (e.g. blue) was absorbed. 
However, the fluorescent probes or fluorescent proteins will be photo-bleached if a high 
density light is delivered. The bilayer membrane or a particular membrane protein is 
uniformly labeled with a fluorescent tag, or the membrane protein is fused with a 
fluorescent protein, such as green fluorescent protein (GFP) or yellow fluorescent 
protein (YFP). The fluorescence is initially evenly distributed on the cell membrane. A 
particular area on the cell membrane is selectively photo-bleached by a small fast light 
pulse. After the photo-bleach, due to the diffusion or active movements of the molecules 
on the cell membrane, the fluorescence intensity in the photo-bleached area will 
increase as the unbleached molecules continuously diffuse into this area, until the 
fluorescence intensity become stabilized over time. By monitoring the recovery of the 
fluorescence intensity after the photo-bleach, the lateral diffusion of the membrane 
proteins could be characterized. 
 
I will make constructs of CXCR2-FL (WT, ∆TTL, and AAA) with YFP tagged at N-
terminus, and co-transfect PDAC cells with pEYFP-CXCR2 (WT, ∆TTL, or AAA) and 
pcDNA3-NHERF1, and perform the FRAP assay to monitor CXCR2 motility. I anticipate 
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that PDAC cells co-overexpressing YFP-CXCR2 (WT) and NHERF1 will show the 
greatest T1/2 (lowest motility), because forming the spatially compact macromolecular 
complex will retard the motility (lateral diffusion) of CXCR2. Also, I will deliver CXCR2 
peptides (WT or ∆TTL) into PDAC cells co-overexpressing EYFP-CXCR2 (WT) and 
NHERF1, and perform the FRAP experiments. I anticipate that CXCR2 peptide (WT) 
will enhance the recovery, whereas CXCR2 peptide (∆TTL) will not.  
 
Besides, I will transfect PDAC cells with pEYFP-CXCR2 (WT), and transduced with α-
NHERF1 lenti-shRNAs or control. Gene sequence-specific shRNA clones anti-NHERF1 
and anti-NHERF2 (containing CTCGAG as the loop sequence)220 have been 
constructed within the lentivirus plasmid vector pLKO.1-puromycin (obtained from Dr. 
Fei Sun at Physiology dept, and Dr. Fei Sun has the expertise with Lentivirus 
construction). The knockdown effect of anti-NHERF1 shRNA constructs have been 
confirmed by transient transfection into a pancreatic cancer cell L3.6pl (data not shown). 
All cells will be subjected to the FRAP experiments. My prediction is that the cells with 
NHERF1 knockdown will show the greatest recovery after photo-bleach, because the 
binding between NHERF1 and CXCR2 could stabilize CXCR2 in the membrane.  
 
I have also planned an alternative approach due to the possibility that I might not detect 
the anticipated difference in my proposed FRAP assays, because FRAP only measures 
the average of the fluorescence recovery (lateral diffusion) in the photo-bleached region, 
not the individual behavior of the single receptor molecule (such as CXCR2). Therefore, 
I will also use single molecule imaging via Total Internal Reflection Fluorescence 
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Microscope (TIRFM) to study the molecular dynamics of individual CXCR2 in the 
plasma membrane. Briefly, PDAC cells will be transduced by Lenti-virus encoding 3HA-
CXCR2-FL. PDAC cells stably expressing 3HA-CXCR2 will be overexpressed with 
NHERF1, and grown on 35-mm glass-bottom dishes. Then, the cells will be incubated 
with biotin α-HA antibody (Sigma-Aldrich, St. Louis, MO), followed by a 2nd incubation 
with streptavidin-conjugated Qdot-655, which specifically binds to biotin, before 
mounted on an inverted fluorescence microscope. The images will be captured at 1 ~ 3 
frames per second for 1 ~ 3min with 50-ms exposure time, 100x oil-immersion objective 
(NA 1.40). Data will be analyzed by SlideBook 4.2 software, which generates the 
diffusion coefficient (D) and mean squared displacement (MSD). To monitor the 
changes in lateral diffusion of CXCR2 with complex disruption, cells will be pre-
delivered with CXCR2 peptide (WT or ∆TTL). 
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ABSTRACT 
CXCR2 MACROMOLECULAR COMPLEX IN PANCREATIC CANCER: A POTENTIAL 
THERAPEUTIC TARGET IN TUMOR GROWTH 
by 
SHUO WANG 
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Degree: Doctor of Philosophy 
The signaling mediated by the chemokine receptor CXC chemokine receptor 2 
(CXCR2) plays an important role in promoting the progression of many cancers, 
including pancreatic cancer, one of the most lethal human malignancies. CXCR2 
possesses a consensus PSD-95/DlgA/ZO-1 (PDZ) motif at its carboxyl termini, which 
might interact with potential PDZ scaffold/adaptor proteins. We have previously reported 
that CXCR2 PDZ motif-mediated protein interaction is an important regulator for 
neutrophil functions. Here, using a series of biochemical assays, we demonstrate that 
CXCR2 is physically coupled to its downstream effector phospholipase C-β3 (PLC-β3) 
that is mediated by PDZ scaffold protein Na(+)/H(+) exchange regulatory factor 1 
(NHERF1) into a macromolecular signaling complex both in vitro and in pancreatic 
cancer cells. We also observe that disrupting the CXCR2 complex, by gene delivery or 
peptide delivery of exogenous CXCR2 C-tail, significantly inhibits the biologic functions 
of pancreatic cancer cells (i.e., proliferation and invasion) in a PDZ motif-dependent 
manner. In addition, using a human pancreatic tumor xenograft model, we show that 
gene delivery of CXCR2 C-tail sequence (containing the PDZ motif) by adeno-
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associated virus type 2 viral vector potently suppresses human pancreatic tumor growth 
in a subcutaneous xenograft mouse model. In summary, our results suggest the 
existence of a physical and functional coupling of CXCR2 and PLC-β3 mediated 
through NHERF1, forming a macromolecular complex that is critical for efficient and 
specific CXCR2 signaling in pancreatic cancer progression. Disrupting this CXCR2 
complex could represent a novel and effective treatment strategy against pancreatic 
cancer. 
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